nct_id,title,study_type,phase,status,sponsor,classification,classification_reason
NCT00002773,"Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,St. Vincent Medical Center - Los Angeles,therapeutic,Interventional study
NCT00003411,"Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,University of Pittsburgh,therapeutic,Interventional study
NCT00003546,Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Alliance for Clinical Trials in Oncology,therapeutic,Interventional study
NCT00003677,Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT00003760,Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,The University of Texas Health Science Center at San Antonio,therapeutic,Interventional study
NCT00003851,"Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer",INTERVENTIONAL,NA,TERMINATED,Columbia University,therapeutic,Interventional study
NCT00004003,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery,INTERVENTIONAL,PHASE2,COMPLETED,Barbara Ann Karmanos Cancer Institute,therapeutic,Interventional study
NCT00004190,Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Alliance for Clinical Trials in Oncology,therapeutic,Interventional study
NCT00004884,Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,European Organisation for Research and Treatment of Cancer - EORTC,therapeutic,Interventional study
NCT00005648,Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",therapeutic,Interventional study
NCT00005869,Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE3,UNKNOWN,"Astex Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT00005871,Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer,INTERVENTIONAL,PHASE3,UNKNOWN,"Astex Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT00006117,Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,GERCOR - Multidisciplinary Oncology Cooperative Group,therapeutic,Interventional study
NCT00016965,BMS-247550 in Treating Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,SWOG Cancer Research Network,therapeutic,Interventional study
NCT00024362,BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery,INTERVENTIONAL,PHASE2,UNKNOWN,Theradex,therapeutic,Interventional study
NCT00024375,DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Theradex,therapeutic,Interventional study
NCT00025168,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Wake Forest University Health Sciences,therapeutic,Interventional study
NCT00026104,Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00026130,Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Alliance for Clinical Trials in Oncology,therapeutic,Interventional study
NCT00026403,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Alliance for Clinical Trials in Oncology,therapeutic,Interventional study
NCT00027521,Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE1,WITHDRAWN,Ichor Medical Systems Incorporated,therapeutic,Interventional study
NCT00028834,Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00030732,Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,Swiss Cancer Institute,therapeutic,Interventional study
NCT00033735,Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,Eisai Inc.,therapeutic,Interventional study
NCT00034827,"A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,Pfizer,therapeutic,Interventional study
NCT00040183,"OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.",INTERVENTIONAL,PHASE3,COMPLETED,OSI Pharmaceuticals,therapeutic,Interventional study
NCT00040833,Acupuncture and Acupressure in Treating Patients With Moderate or Severe Pain Related to Stage III or Stage IV Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT00042939,Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Eastern Cooperative Oncology Group,therapeutic,Interventional study
NCT00047307,"Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00051467,A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,GenVec,therapeutic,Interventional study
NCT00052689,Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00053222,Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine,INTERVENTIONAL,PHASE2,COMPLETED,University of Chicago,therapeutic,Interventional study
NCT00053924,Perifosine in Treating Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"University Health Network, Toronto",therapeutic,Interventional study
NCT00055250,"A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,Eli Lilly and Company,therapeutic,Interventional study
NCT00056537,"ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,Active Biotech AB,therapeutic,Interventional study
NCT00058149,Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,Eastern Cooperative Oncology Group,therapeutic,Interventional study
NCT00058201,Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,Royal Liverpool University Hospital,therapeutic,Interventional study
NCT00059826,Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Alliance for Clinical Trials in Oncology,therapeutic,Interventional study
NCT00064051,3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Vion Pharmaceuticals,therapeutic,Interventional study
NCT00064207,Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,European Organisation for Research and Treatment of Cancer - EORTC,therapeutic,Interventional study
NCT00075647,CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00077519,Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Abramson Cancer Center at Penn Medicine,therapeutic,Interventional study
NCT00081549,Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies,INTERVENTIONAL,PHASE1,UNKNOWN,Aronex Pharmaceuticals,therapeutic,Interventional study
NCT00088894,Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00089024,"Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,University of Nebraska,therapeutic,Interventional study
NCT00094445,Trial of Curcumin in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT00095966,Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00096070,"Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00102700,ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",therapeutic,Interventional study
NCT00109941,Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery,INTERVENTIONAL,PHASE2,COMPLETED,Milton S. Hershey Medical Center,therapeutic,Interventional study
NCT00111904,Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Theradex,therapeutic,Interventional study
NCT00112580,MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery,INTERVENTIONAL,PHASE2,COMPLETED,Bristol-Myers Squibb,therapeutic,Interventional study
NCT00112658,Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,UNICANCER,therapeutic,Interventional study
NCT00112697,Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,INTERVENTIONAL,PHASE2,COMPLETED,UNICANCER,therapeutic,Interventional study
NCT00113256,Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,"Astex Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT00121745,Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,Epeius Biotechnologies,therapeutic,Interventional study
NCT00126633,"Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,"University of California, San Francisco",therapeutic,Interventional study
NCT00136669,Acupuncture For Pancreatic Cancer Pain,INTERVENTIONAL,PHASE3,COMPLETED,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT00154791,Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,COMPLETED,National Taiwan University Hospital,therapeutic,Interventional study
NCT00161213,Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,University of Medicine and Dentistry of New Jersey,therapeutic,Interventional study
NCT00176813,"Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,University of Michigan Rogel Cancer Center,therapeutic,Interventional study
NCT00177853,"Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer",INTERVENTIONAL,PHASE1,TERMINATED,University of Pittsburgh,therapeutic,Interventional study
NCT00192842,Gemcitabine With Curcumin for Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Rambam Health Care Campus,therapeutic,Interventional study
NCT00203892,Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,COMPLETED,University of Chicago,therapeutic,Interventional study
NCT00209677,Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,SUSPENDED,Hokkaido Gastrointestinal Cancer Study Group,therapeutic,Interventional study
NCT00219557,AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Pfizer,therapeutic,Interventional study
NCT00225745,Ghrelin Levels in Pancreatic Cancer Patients,OBSERVATIONAL,Unknown,COMPLETED,Dartmouth-Hitchcock Medical Center,other,Does not match therapeutic or biomarker criteria
NCT00242190,"Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,University of Michigan Rogel Cancer Center,therapeutic,Interventional study
NCT00245362,A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Cell Genesys,therapeutic,Interventional study
NCT00251355,"Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,Dana-Farber Cancer Institute,therapeutic,Interventional study
NCT00253526,Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer,INTERVENTIONAL,PHASE2,WITHDRAWN,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00261092,GEMOX: Oxaliplatin in Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Sanofi,therapeutic,Interventional study
NCT00262951,Chemoradiation in Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,"Masonic Cancer Center, University of Minnesota",therapeutic,Interventional study
NCT00265876,AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,INTERVENTIONAL,PHASE1,COMPLETED,NCIC Clinical Trials Group,therapeutic,Interventional study
NCT00275119,"Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery",INTERVENTIONAL,PHASE2,UNKNOWN,GERCOR - Multidisciplinary Oncology Cooperative Group,therapeutic,Interventional study
NCT00290693,Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,University of Miami,therapeutic,Interventional study
NCT00296114,Pancreatic Cancer Serum and DNA Repository,OBSERVATIONAL,Unknown,COMPLETED,Pancreatic Cancer Research Team,other,Does not match therapeutic or biomarker criteria
NCT00310050,"Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE1,TERMINATED,Wake Forest University Health Sciences,therapeutic,Interventional study
NCT00316420,Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Swedish Medical Center,therapeutic,Interventional study
NCT00323583,Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Seattle Cancer Treatment and Wellness Center,therapeutic,Interventional study
NCT00324428,TMS for the Treatment of Pancreatic Cancer Pain,INTERVENTIONAL,NA,COMPLETED,Beth Israel Deaconess Medical Center,therapeutic,Interventional study
NCT00326911,Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Eli Lilly and Company,therapeutic,Interventional study
NCT00331682,Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00335543,"Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery",INTERVENTIONAL,PHASE2,COMPLETED,Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft,therapeutic,Interventional study
NCT00358566,GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer,INTERVENTIONAL,PHASE3,TERMINATED,Pharmexa A/S,therapeutic,Interventional study
NCT00369460,Changes in Muscle Tissue in Patients With Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Case Comprehensive Cancer Center,other,Does not match therapeutic or biomarker criteria
NCT00372944,"AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy",INTERVENTIONAL,PHASE2,COMPLETED,AstraZeneca,therapeutic,Interventional study
NCT00376948,"Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,Barbara Ann Karmanos Cancer Institute,therapeutic,Interventional study
NCT00383760,"Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients",INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00386399,Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene,INTERVENTIONAL,PHASE2,WITHDRAWN,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT00395252,Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Carmen Schade-Brittinger,therapeutic,Interventional study
NCT00408564,"Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery",INTERVENTIONAL,PHASE2,COMPLETED,Medical University of South Carolina,therapeutic,Interventional study
NCT00410774,Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery,INTERVENTIONAL,PHASE1,TERMINATED,"University of California, San Francisco",therapeutic,Interventional study
NCT00414570,An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs,INTERVENTIONAL,EARLY_PHASE1,TERMINATED,AHS Cancer Control Alberta,therapeutic,Interventional study
NCT00417209,Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen,INTERVENTIONAL,PHASE3,COMPLETED,Sanofi,therapeutic,Interventional study
NCT00425360,Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,Royal Liverpool University Hospital,therapeutic,Interventional study
NCT00448838,"Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",INTERVENTIONAL,NA,COMPLETED,University of Miami,therapeutic,Interventional study
NCT00460174,"Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,Northwestern University,therapeutic,Interventional study
NCT00462852,Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Hull University Teaching Hospitals NHS Trust,therapeutic,Interventional study
NCT00470535,Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Roswell Park Cancer Institute,therapeutic,Interventional study
NCT00471146,Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.,INTERVENTIONAL,PHASE3,COMPLETED,Pfizer,therapeutic,Interventional study
NCT00474812,Dasatinib in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00478010,"Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer",INTERVENTIONAL,NA,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT00489671,Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis,OBSERVATIONAL,Unknown,COMPLETED,Wake Forest University Health Sciences,biomarker,Biomarker or molecular study
NCT00490373,Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic,INTERVENTIONAL,PHASE2,COMPLETED,Eli Lilly and Company,therapeutic,Interventional study
NCT00495924,Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,COMPLETED,KU Leuven,biomarker,Biomarker or molecular study
NCT00498225,Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,"Taiho Pharmaceutical Co., Ltd.",therapeutic,Interventional study
NCT00499265,Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery,INTERVENTIONAL,PHASE2,COMPLETED,Heidelberg Pharma AG,therapeutic,Interventional study
NCT00514163,GEM vs GEM+TS-1 for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Japan Clinical Cancer Research Organization,therapeutic,Interventional study
NCT00521404,Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Daiichi Sankyo,therapeutic,Interventional study
NCT00536874,Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery,INTERVENTIONAL,PHASE2,COMPLETED,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT00544908,Dasatinib in Treating Patients With Stage IV Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,City of Hope Medical Center,therapeutic,Interventional study
NCT00547144,Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,George Albert Fisher,therapeutic,Interventional study
NCT00551057,Expression of Inflammatory Proteins in Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,University of Zurich,biomarker,Biomarker or molecular study
NCT00553813,"A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer",INTERVENTIONAL,PHASE2,TERMINATED,"Cortice Biosciences, Inc.",therapeutic,Interventional study
NCT00556023,"A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,AstraZeneca,therapeutic,Interventional study
NCT00559598,Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer,OBSERVATIONAL,Unknown,COMPLETED,National Institutes of Health Clinical Center (CC),biomarker,Biomarker or molecular study
NCT00565487,Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Milton S. Hershey Medical Center,therapeutic,Interventional study
NCT00568646,Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"CASI Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT00578279,Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study,INTERVENTIONAL,PHASE4,COMPLETED,Indiana University,therapeutic,Interventional study
NCT00582699,"Depression, Cytokines and Pancreatic Cancer",OBSERVATIONAL,Unknown,COMPLETED,Memorial Sloan Kettering Cancer Center,other,Does not match therapeutic or biomarker criteria
NCT00585078,Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,COMPLETED,Beth Israel Deaconess Medical Center,therapeutic,Interventional study
NCT00587132,Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,TERMINATED,Mayo Clinic,therapeutic,Interventional study
NCT00599833,Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery,INTERVENTIONAL,PHASE2,COMPLETED,The Christie NHS Foundation Trust,therapeutic,Interventional study
NCT00614601,Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,NewLink Genetics Corporation,therapeutic,Interventional study
NCT00614653,"Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT00617708,S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery,INTERVENTIONAL,PHASE1,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT00630552,QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"NantCell, Inc.",therapeutic,Interventional study
NCT00637247,A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,AmpliMed Corporation,therapeutic,Interventional study
NCT00639925,Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer,INTERVENTIONAL,PHASE1,UNKNOWN,Fukushima Medical University,therapeutic,Interventional study
NCT00642733,A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE4,TERMINATED,Hoffmann-La Roche,therapeutic,Interventional study
NCT00644254,The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,COMPLETED,KU Leuven,biomarker,Biomarker or molecular study
NCT00651742,Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"Taiho Oncology, Inc.",therapeutic,Interventional study
NCT00667082,"NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",INTERVENTIONAL,PHASE1,COMPLETED,Celgene,therapeutic,Interventional study
NCT00673504,First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Central European Society for Anticancer Drug Research,therapeutic,Interventional study
NCT00674973,A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Hoffmann-La Roche,therapeutic,Interventional study
NCT00683085,Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,Tokyo University,therapeutic,Interventional study
NCT00683358,Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,UNKNOWN,Tokyo University,therapeutic,Interventional study
NCT00690300,Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,University of Ulm,therapeutic,Interventional study
NCT00707278,Radiation Therapy and Capecitabine/Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma,INTERVENTIONAL,PHASE1,COMPLETED,University of Utah,therapeutic,Interventional study
NCT00709826,APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"Tragara Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT00711997,Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Anchiano Therapeutics Israel Ltd.,therapeutic,Interventional study
NCT00726037,"A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE2,TERMINATED,Loyola University,therapeutic,Interventional study
NCT00733850,Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,KangLaiTe USA,therapeutic,Interventional study
NCT00769652,"Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer",INTERVENTIONAL,NA,TERMINATED,"Rutgers, The State University of New Jersey",therapeutic,Interventional study
NCT00786006,Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Asan Medical Center,therapeutic,Interventional study
NCT00805688,Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,M.D. Anderson Cancer Center,biomarker,Biomarker or molecular study
NCT00813163,Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,PharmaEngine,therapeutic,Interventional study
NCT00813696,Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,UNKNOWN,Istituti Tumori Giovanni Paolo II,therapeutic,Interventional study
NCT00826982,Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Mayo Clinic,biomarker,Biomarker or molecular study
NCT00830557,Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders,OBSERVATIONAL,Unknown,RECRUITING,Mayo Clinic,biomarker,Biomarker or molecular study
NCT00836407,"Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT00837135,GI-4000 With Adoptive Transfer in Pancreatic Cancer,INTERVENTIONAL,PHASE1,WITHDRAWN,University of Pennsylvania,therapeutic,Interventional study
NCT00837239,Huachansu & Gemcitabine in Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT00837876,Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,INTERVENTIONAL,PHASE2,COMPLETED,Vanderbilt-Ingram Cancer Center,therapeutic,Interventional study
NCT00854477,Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE4,COMPLETED,Cambridge University Hospitals NHS Foundation Trust,therapeutic,Interventional study
NCT00855634,Resection in Pancreatic Cancer With Minimal Metastatic Disease or Venous Infiltration Trial at Technische Universität München,INTERVENTIONAL,NA,TERMINATED,Technical University of Munich,therapeutic,Interventional study
NCT00868114,Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Leo W. Jenkins Cancer Center,therapeutic,Interventional study
NCT00873353,Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,COMPLETED,Grupo Gallego de Investigaciones Oncologicas,therapeutic,Interventional study
NCT00882310,"A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,Columbia University,therapeutic,Interventional study
NCT00882765,Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,INTERVENTIONAL,PHASE2,WITHDRAWN,Jonsson Comprehensive Cancer Center,therapeutic,Interventional study
NCT00882973,Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Samyang Biopharmaceuticals Corporation,therapeutic,Interventional study
NCT00889187,Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,Dana-Farber Cancer Institute,therapeutic,Interventional study
NCT00897494,Identification of Biomarkers for Early Detection of Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Barbara Ann Karmanos Cancer Institute,biomarker,Biomarker or molecular study
NCT00900003,Studying Biomarkers in Patients With Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Vanderbilt-Ingram Cancer Center,biomarker,Biomarker or molecular study
NCT00900016,Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery,OBSERVATIONAL,Unknown,COMPLETED,Fox Chase Cancer Center,biomarker,Biomarker or molecular study
NCT00902291,A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Astellas Pharma Inc,therapeutic,Interventional study
NCT00910741,NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia,INTERVENTIONAL,PHASE1,COMPLETED,"NanoCarrier Co., Ltd.",therapeutic,Interventional study
NCT00913198,A Study of CP-4126 in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Clavis Pharma,therapeutic,Interventional study
NCT00919659,Parenteral Nutrition Support for Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,CONKO-Studiengruppe,therapeutic,Interventional study
NCT00925769,"ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,Hoffmann-La Roche,therapeutic,Interventional study
NCT00936104,Side Population in Pancreatic Ductal Adenocarcinoma (PDAC),OBSERVATIONAL,Unknown,COMPLETED,"University Hospital, Gasthuisberg",biomarker,Biomarker or molecular study
NCT00950144,"Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer",OBSERVATIONAL,Unknown,COMPLETED,City of Hope Medical Center,biomarker,Biomarker or molecular study
NCT00954525,Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Sidney Kimmel Cancer Center at Thomas Jefferson University,therapeutic,Interventional study
NCT00960284,"Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,IRCCS San Raffaele,therapeutic,Interventional study
NCT00962312,Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Cancer Trials Ireland,therapeutic,Interventional study
NCT00966277,Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients,INTERVENTIONAL,PHASE4,COMPLETED,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT00967291,Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,IRCCS San Raffaele,therapeutic,Interventional study
NCT00967603,Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,IRCCS San Raffaele,therapeutic,Interventional study
NCT00968604,C-VISA BikDD: Liposome in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,WITHDRAWN,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT00974610,"Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.",OBSERVATIONAL,Unknown,COMPLETED,Cancer Trials Ireland,biomarker,Biomarker or molecular study
NCT00987766,"Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer",INTERVENTIONAL,PHASE1,COMPLETED,Vanderbilt-Ingram Cancer Center,therapeutic,Interventional study
NCT01016483,Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,EMD Serono,therapeutic,Interventional study
NCT01017822,"Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE1,WITHDRAWN,Radiation Therapy Oncology Group,therapeutic,Interventional study
NCT01019382,A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"University Hospitals, Leicester",therapeutic,Interventional study
NCT01042028,"A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer",INTERVENTIONAL,PHASE1,TERMINATED,Per Pfeiffer,therapeutic,Interventional study
NCT01050283,A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144),INTERVENTIONAL,PHASE1,TERMINATED,Merck Sharp & Dohme LLC,therapeutic,Interventional study
NCT01050426,"A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)",INTERVENTIONAL,PHASE2,TERMINATED,Royal Marsden NHS Foundation Trust,therapeutic,Interventional study
NCT01056601,Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy,INTERVENTIONAL,PHASE2,TERMINATED,"Masonic Cancer Center, University of Minnesota",therapeutic,Interventional study
NCT01063192,A Study of Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,"National Health Research Institutes, Taiwan",therapeutic,Interventional study
NCT01074996,Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers,INTERVENTIONAL,PHASE2,UNKNOWN,The Affiliated Hospital of the Chinese Academy of Military Medical Sciences,therapeutic,Interventional study
NCT01086332,Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,University of Iowa,therapeutic,Interventional study
NCT01092689,The Role of Meat-borne Carcinogens in Pancreatic Cancer,INTERVENTIONAL,PHASE1,WITHDRAWN,University of Minnesota,therapeutic,Interventional study
NCT01094626,Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection,INTERVENTIONAL,NA,WITHDRAWN,Elizabeth Hecht,therapeutic,Interventional study
NCT01096732,Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS),INTERVENTIONAL,PHASE2,TERMINATED,Lisa Bax,therapeutic,Interventional study
NCT01098344,MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery,INTERVENTIONAL,PHASE1,COMPLETED,Cancer Research UK,therapeutic,Interventional study
NCT01102569,Pancreatic Cancer Genetics,OBSERVATIONAL,Unknown,RECRUITING,Columbia University,biomarker,Biomarker or molecular study
NCT01104129,Stool Testing for Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Columbia University,other,Does not match therapeutic or biomarker criteria
NCT01118897,Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers,INTERVENTIONAL,PHASE1,COMPLETED,Tata Memorial Hospital,therapeutic,Interventional study
NCT01121848,Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,Sanofi,therapeutic,Interventional study
NCT01124786,A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP),INTERVENTIONAL,PHASE2,COMPLETED,"Clovis Oncology, Inc.",therapeutic,Interventional study
NCT01127815,Identify the Clinical Significance and Potential Implications of Peritoneal Washing Cytology (PWC) in Patients With Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,National Taiwan University Hospital,other,Does not match therapeutic or biomarker criteria
NCT01130142,A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"Infinity Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT01144455,Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,COMPLETED,ImmunoGenesis,therapeutic,Interventional study
NCT01150630,"Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,IRCCS San Raffaele,therapeutic,Interventional study
NCT01167738,Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,IRCCS San Raffaele,therapeutic,Interventional study
NCT01167816,Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,University of Oklahoma,therapeutic,Interventional study
NCT01186731,Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,INSYS Therapeutics Inc,therapeutic,Interventional study
NCT01195415,Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT01198522,Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients,INTERVENTIONAL,PHASE1,TERMINATED,Philogen S.p.A.,therapeutic,Interventional study
NCT01206296,Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,TERMINATED,Medstar Health Research Institute,therapeutic,Interventional study
NCT01210911,Metformin Combined With Chemotherapy for Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),therapeutic,Interventional study
NCT01214720,A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,Hoffmann-La Roche,therapeutic,Interventional study
NCT01231581,Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,GlaxoSmithKline,therapeutic,Interventional study
NCT01234935,Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery,INTERVENTIONAL,PHASE2,COMPLETED,Translational Oncology Research International,therapeutic,Interventional study
NCT01272791,Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Peregrine Pharmaceuticals,therapeutic,Interventional study
NCT01274455,Gene Therapy of Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE1,COMPLETED,"University Hospital, Toulouse",therapeutic,Interventional study
NCT01296763,Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT01298011,Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Pancreatic Cancer Research Team,therapeutic,Interventional study
NCT01314027,Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE3,TERMINATED,University of Zurich,therapeutic,Interventional study
NCT01326364,Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection,OBSERVATIONAL,Unknown,TERMINATED,Stanford University,biomarker,Biomarker or molecular study
NCT01342354,Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,University of Chicago,therapeutic,Interventional study
NCT01373164,A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Eli Lilly and Company,therapeutic,Interventional study
NCT01383538,FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,COMPLETED,Andrew Ko,therapeutic,Interventional study
NCT01385956,SOM 230 and Gemcitabine in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,H. Lee Moffitt Cancer Center and Research Institute,therapeutic,Interventional study
NCT01389440,Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Grupo Espanol Multidisciplinario del Cancer Digestivo,therapeutic,Interventional study
NCT01395017,Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"Otsuka Pharmaceutical Development & Commercialization, Inc.",therapeutic,Interventional study
NCT01401387,Pancreatic Enzyme Suppletion in Pancreatic Cancer,INTERVENTIONAL,PHASE4,WITHDRAWN,Foundation for Liver Research,therapeutic,Interventional study
NCT01415713,The Study of Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,COMPLETED,"National Health Research Institutes, Taiwan",therapeutic,Interventional study
NCT01419483,Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer,INTERVENTIONAL,NA,TERMINATED,University of Iowa,therapeutic,Interventional study
NCT01431794,Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,TERMINATED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT01442974,Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,Grupo Hospital de Madrid,therapeutic,Interventional study
NCT01448668,"Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)",OBSERVATIONAL,Unknown,UNKNOWN,IFAG AG,other,Does not match therapeutic or biomarker criteria
NCT01453153,Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Halozyme Therapeutics,therapeutic,Interventional study
NCT01458717,Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Seoul National University Hospital,therapeutic,Interventional study
NCT01470417,Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,COMPLETED,University of Florida,therapeutic,Interventional study
NCT01473303,Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,WITHDRAWN,Alliance for Clinical Trials in Oncology,therapeutic,Interventional study
NCT01486329,"VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,Vaximm GmbH,therapeutic,Interventional study
NCT01489865,ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Georgetown University,therapeutic,Interventional study
NCT01494155,Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Massachusetts General Hospital,therapeutic,Interventional study
NCT01506973,A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Abramson Cancer Center at Penn Medicine,therapeutic,Interventional study
NCT01510561,A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.,INTERVENTIONAL,PHASE1,WITHDRAWN,Gilead Sciences,therapeutic,Interventional study
NCT01523457,Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Yale University,therapeutic,Interventional study
NCT01523808,Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,ERYtech Pharma,therapeutic,Interventional study
NCT01553019,Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,University of Florida,therapeutic,Interventional study
NCT01569282,Double Bypass Versus Stent-treatment in Irresectable Pancreatic Cancer,INTERVENTIONAL,NA,WITHDRAWN,Göteborg University,therapeutic,Interventional study
NCT01580241,Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,University of Oklahoma,other,Does not match therapeutic or biomarker criteria
NCT01591733,FOLFIRINOX + RT for Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Massachusetts General Hospital,therapeutic,Interventional study
NCT01598584,Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer,INTERVENTIONAL,PHASE2,WITHDRAWN,Tianjin Medical University Cancer Institute and Hospital,therapeutic,Interventional study
NCT01600807,OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas,INTERVENTIONAL,PHASE1,WITHDRAWN,Dana-Farber Cancer Institute,therapeutic,Interventional study
NCT01608711,A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002,INTERVENTIONAL,PHASE2,COMPLETED,"Agensys, Inc.",therapeutic,Interventional study
NCT01621243,M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,"Momenta Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT01628458,Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,UMC Utrecht,therapeutic,Interventional study
NCT01632306,A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,Eli Lilly and Company,therapeutic,Interventional study
NCT01658943,Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT01660971,"Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery",INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),therapeutic,Interventional study
NCT01665625,Regional Versus Systemic Chemotherapy in the Treatment of Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,"Air Force Military Medical University, China",therapeutic,Interventional study
NCT01675258,"Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers",OBSERVATIONAL,Unknown,UNKNOWN,Hadassah Medical Organization,biomarker,Biomarker or molecular study
NCT01676259,A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Silenseed Ltd,therapeutic,Interventional study
NCT01693276,"Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer",INTERVENTIONAL,PHASE1,TERMINATED,Olugbenga Olowokure,therapeutic,Interventional study
NCT01693523,Minocycline Study in Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,COMPLETED,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT01703026,Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses,OBSERVATIONAL,Unknown,COMPLETED,Changi General Hospital,other,Does not match therapeutic or biomarker criteria
NCT01729481,Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Ludwig-Maximilians - University of Munich,therapeutic,Interventional study
NCT01754623,GTX-RT in Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,H. Lee Moffitt Cancer Center and Research Institute,therapeutic,Interventional study
NCT01760694,Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer,INTERVENTIONAL,NA,TERMINATED,Southwestern Regional Medical Center,therapeutic,Interventional study
NCT01764659,4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation,OBSERVATIONAL,Unknown,COMPLETED,"University of Maryland, Baltimore",biomarker,Biomarker or molecular study
NCT01770132,Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,John DeWitt,therapeutic,Interventional study
NCT01774643,A Study of Pancreatic Cancer in Xenografts From Liver Metastases,OBSERVATIONAL,Unknown,COMPLETED,"University Health Network, Toronto",other,Does not match therapeutic or biomarker criteria
NCT01782690,An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Hoffmann-La Roche,other,Does not match therapeutic or biomarker criteria
NCT01786850,Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer,EXPANDED_ACCESS,Unknown,AVAILABLE,University of Roma La Sapienza,other,Does not match therapeutic or biomarker criteria
NCT01808638,Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02),INTERVENTIONAL,PHASE1,COMPLETED,Silence Therapeutics GmbH,therapeutic,Interventional study
NCT01821612,Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,COMPLETED,Alliance for Clinical Trials in Oncology,therapeutic,Interventional study
NCT01821729,Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Massachusetts General Hospital,therapeutic,Interventional study
NCT01835041,CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Wake Forest University Health Sciences,therapeutic,Interventional study
NCT01836432,Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE3,TERMINATED,NewLink Genetics Corporation,therapeutic,Interventional study
NCT01839981,CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Wake Forest University Health Sciences,therapeutic,Interventional study
NCT01844817,Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"SCRI Development Innovations, LLC",therapeutic,Interventional study
NCT01851174,Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Western Regional Medical Center,therapeutic,Interventional study
NCT01852890,"Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I",INTERVENTIONAL,PHASE1,COMPLETED,Joseph J. Cullen,therapeutic,Interventional study
NCT01876069,Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Suspected Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,Samsung Medical Center,therapeutic,Interventional study
NCT01896869,FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT01897636,Efficacy and Safety of Endoscopic Ultrasound Guided Fine-needle Injection of Dendritic Cells Vaccination Into Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,therapeutic,Interventional study
NCT01898741,Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,UMC Utrecht,therapeutic,Interventional study
NCT01900327,Neoadjuvant Treatment in Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE3,TERMINATED,Universitätsklinikum Hamburg-Eppendorf,therapeutic,Interventional study
NCT01903083,Chemoimmunotherapy and Radiation in Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Providence Health & Services,therapeutic,Interventional study
NCT01911416,A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer,INTERVENTIONAL,NA,WITHDRAWN,University of Utah,therapeutic,Interventional study
NCT01945879,Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,CONKO-Studiengruppe,therapeutic,Interventional study
NCT01946646,Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,National Taiwan University Hospital,therapeutic,Interventional study
NCT01954732,Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery,INTERVENTIONAL,PHASE1,WITHDRAWN,Case Comprehensive Cancer Center,therapeutic,Interventional study
NCT01954992,Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE3,RECRUITING,Eleison Pharmaceuticals LLC.,therapeutic,Interventional study
NCT01959139,"S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,SWOG Cancer Research Network,therapeutic,Interventional study
NCT01964287,First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.,INTERVENTIONAL,PHASE1,COMPLETED,Institut du Cancer de Montpellier - Val d'Aurelle,therapeutic,Interventional study
NCT01971034,Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.,INTERVENTIONAL,PHASE2,COMPLETED,Instituto do Cancer do Estado de São Paulo,therapeutic,Interventional study
NCT01977066,Exercise Intervention Study for Pancreatic Cancer Patients,INTERVENTIONAL,NA,COMPLETED,German Cancer Research Center,therapeutic,Interventional study
NCT01983410,A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,biomarker,Biomarker or molecular study
NCT01989000,The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome,INTERVENTIONAL,NA,COMPLETED,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),therapeutic,Interventional study
NCT01989624,PAncreatic Adenocarcinoma in Hospital,OBSERVATIONAL,Unknown,COMPLETED,Centre Hospitalier Departemental Vendee,other,Does not match therapeutic or biomarker criteria
NCT01995240,Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study,INTERVENTIONAL,NA,COMPLETED,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),therapeutic,Interventional study
NCT02004262,Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,INTERVENTIONAL,PHASE2,COMPLETED,"Aduro Biotech, Inc.",therapeutic,Interventional study
NCT02017015,Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Celgene,therapeutic,Interventional study
NCT02047474,Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Yale University,therapeutic,Interventional study
NCT02050178,Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"OncoMed Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT02079623,Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Aalborg University Hospital,biomarker,Biomarker or molecular study
NCT02092948,"Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,Jonsson Comprehensive Cancer Center,therapeutic,Interventional study
NCT02106871,Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer,INTERVENTIONAL,PHASE1,WITHDRAWN,"The University of Texas Medical Branch, Galveston",therapeutic,Interventional study
NCT02109341,Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Gruppo Oncologico Italiano di Ricerca Clinica,therapeutic,Interventional study
NCT02109445,Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies,INTERVENTIONAL,PHASE2,TERMINATED,Pfizer,therapeutic,Interventional study
NCT02117258,Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,COMPLETED,Zeria Pharmaceutical,therapeutic,Interventional study
NCT02117479,Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),INTERVENTIONAL,PHASE3,TERMINATED,Incyte Corporation,therapeutic,Interventional study
NCT02118077,Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,Cancer Advances Inc.,therapeutic,Interventional study
NCT02119663,A Study of Ruxolitinib in Pancreatic Cancer Patients,INTERVENTIONAL,PHASE3,TERMINATED,Incyte Corporation,therapeutic,Interventional study
NCT02124317,Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Chinese PLA General Hospital,therapeutic,Interventional study
NCT02125136,Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,AIO-Studien-gGmbH,therapeutic,Interventional study
NCT02131493,S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Zhejiang University,therapeutic,Interventional study
NCT02138383,Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,H. Lee Moffitt Cancer Center and Research Institute,therapeutic,Interventional study
NCT02148549,Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study,INTERVENTIONAL,PHASE1,COMPLETED,Wakayama Medical University,therapeutic,Interventional study
NCT02153450,Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,COMPLETED,Case Comprehensive Cancer Center,therapeutic,Interventional study
NCT02155088,BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,H. Lee Moffitt Cancer Center and Research Institute,therapeutic,Interventional study
NCT02159248,"Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation",INTERVENTIONAL,PHASE1,WITHDRAWN,"Orlando Health, Inc.",therapeutic,Interventional study
NCT02174887,Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Institut Paoli-Calmettes,therapeutic,Interventional study
NCT02178436,"Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,Mohammed Najeeb Al Hallak,therapeutic,Interventional study
NCT02194829,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery,INTERVENTIONAL,PHASE1,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT02202785,A Study of MLN0264 in Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,"Millennium Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT02206360,Pancreatic Cancer Early Detection Program,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,White Plains Hospital,biomarker,Biomarker or molecular study
NCT02241187,Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection,INTERVENTIONAL,NA,COMPLETED,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT02243358,Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Henry Ford Health System,therapeutic,Interventional study
NCT02245217,Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients,INTERVENTIONAL,NA,COMPLETED,University of Utah,therapeutic,Interventional study
NCT02261714,Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Targovax ASA,therapeutic,Interventional study
NCT02269683,Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer,INTERVENTIONAL,NA,WITHDRAWN,Technische Universität Dresden,therapeutic,Interventional study
NCT02272738,A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Osaka Medical Center for Cancer and Cardiovascular Diseases,therapeutic,Interventional study
NCT02289898,"Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma",INTERVENTIONAL,PHASE2,COMPLETED,"OncoMed Pharmaceuticals, Inc.",therapeutic,Interventional study
NCT02301143,Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC),INTERVENTIONAL,PHASE2,COMPLETED,Celgene,therapeutic,Interventional study
NCT02309632,Pancreatic Cancer Screening of High-Risk Individuals in Arkansas,INTERVENTIONAL,NA,WITHDRAWN,University of Arkansas,therapeutic,Interventional study
NCT02324543,Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT02329717,Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,UNKNOWN,"Phoenix Biotechnology, Inc",therapeutic,Interventional study
NCT02332863,Comparison of Back-loaded vs Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement in Pancreatic Cancer.,INTERVENTIONAL,NA,COMPLETED,"University of Colorado, Denver",therapeutic,Interventional study
NCT02333409,Acupuncture for Pain Control in Patients With Inoperable Pancreatic Cancer,INTERVENTIONAL,NA,TERMINATED,Chinese University of Hong Kong,therapeutic,Interventional study
NCT02336087,"Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery",INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,City of Hope Medical Center,therapeutic,Interventional study
NCT02343835,Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,"Fuda Cancer Hospital, Guangzhou",therapeutic,Interventional study
NCT02345408,Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,COMPLETED,Amgen,therapeutic,Interventional study
NCT02347618,Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,University of Rochester,therapeutic,Interventional study
NCT02351219,FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"Azienda Ospedaliero, Universitaria Pisana",therapeutic,Interventional study
NCT02352337,First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem,INTERVENTIONAL,PHASE2,COMPLETED,Federation Francophone de Cancerologie Digestive,therapeutic,Interventional study
NCT02368860,"OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma",INTERVENTIONAL,PHASE1,COMPLETED,"National Cancer Centre, Singapore",therapeutic,Interventional study
NCT02383433,Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Case Comprehensive Cancer Center,therapeutic,Interventional study
NCT02394535,"Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT02399137,A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Merrimack Pharmaceuticals,therapeutic,Interventional study
NCT02404363,Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy,INTERVENTIONAL,PHASE3,TERMINATED,Assistance Publique - Hôpitaux de Paris,therapeutic,Interventional study
NCT02414100,Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy,OBSERVATIONAL,Unknown,WITHDRAWN,Sidney Kimmel Cancer Center at Thomas Jefferson University,biomarker,Biomarker or molecular study
NCT02416609,Low-dose Radiotherapy Plus Chemotherapy With Gem-based Doublets and Stereotactic Radiotherapy for Advanced Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Azienda Ospedaliero-Universitaria di Modena,therapeutic,Interventional study
NCT02424279,Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder,INTERVENTIONAL,NA,UNKNOWN,Medical University of Gdansk,therapeutic,Interventional study
NCT02428270,A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"University Health Network, Toronto",therapeutic,Interventional study
NCT02436668,"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)",INTERVENTIONAL,PHASE3,COMPLETED,Pharmacyclics LLC.,therapeutic,Interventional study
NCT02440958,Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial,INTERVENTIONAL,PHASE2,COMPLETED,Yonsei University,therapeutic,Interventional study
NCT02442323,A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients,INTERVENTIONAL,NA,COMPLETED,Fox Chase Cancer Center,therapeutic,Interventional study
NCT02451384,According CTC to Compare the Influences of Different Methods to Remove the PDAC,INTERVENTIONAL,NA,UNKNOWN,Shanghai Zhongshan Hospital,therapeutic,Interventional study
NCT02454140,Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,"University of California, San Diego",therapeutic,Interventional study
NCT02456051,Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients,OBSERVATIONAL,Unknown,TERMINATED,University of Roma La Sapienza,biomarker,Biomarker or molecular study
NCT02468557,Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE1,TERMINATED,Gilead Sciences,therapeutic,Interventional study
NCT02487277,"PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma",INTERVENTIONAL,PHASE2,TERMINATED,Andrew Ko,therapeutic,Interventional study
NCT02506842,Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection,INTERVENTIONAL,PHASE3,UNKNOWN,Fudan University,therapeutic,Interventional study
NCT02514421,Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,COMPLETED,"The University of Texas Health Science Center, Houston",therapeutic,Interventional study
NCT02529579,Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,UNKNOWN,Changhai Hospital,therapeutic,Interventional study
NCT02548169,Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,Baylor Research Institute,therapeutic,Interventional study
NCT02550327,"Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer",INTERVENTIONAL,EARLY_PHASE1,COMPLETED,Baylor Research Institute,therapeutic,Interventional study
NCT02550847,Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,National Taiwan University Hospital,biomarker,Biomarker or molecular study
NCT02555813,Treatment of Pancreatic Cancer With Abraxane,OBSERVATIONAL,Unknown,COMPLETED,Celgene,other,Does not match therapeutic or biomarker criteria
NCT02558868,Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Zhejiang University,therapeutic,Interventional study
NCT02562716,S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,INTERVENTIONAL,PHASE2,COMPLETED,SWOG Cancer Research Network,therapeutic,Interventional study
NCT02562898,Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Margaret Tempero,therapeutic,Interventional study
NCT02575508,Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,WITHDRAWN,Roswell Park Cancer Institute,therapeutic,Interventional study
NCT02591082,Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter,OBSERVATIONAL,Unknown,COMPLETED,RenovoRx,other,Does not match therapeutic or biomarker criteria
NCT02592395,Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,WITHDRAWN,"The University of Texas Health Science Center, Houston",therapeutic,Interventional study
NCT02608229,BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,Washington University School of Medicine,therapeutic,Interventional study
NCT02620865,BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Barbara Ann Karmanos Cancer Institute,therapeutic,Interventional study
NCT02635971,Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Fudan University,therapeutic,Interventional study
NCT02643498,A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT02650804,BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,COMPLETED,BPGbio,therapeutic,Interventional study
NCT02682082,EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer,INTERVENTIONAL,NA,TERMINATED,Centre hospitalier de l'Université de Montréal (CHUM),therapeutic,Interventional study
NCT02705196,LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer,INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,Lokon Pharma AB,therapeutic,Interventional study
NCT02707159,Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,COMPLETED,Helse Stavanger HF,therapeutic,Interventional study
NCT02717091,Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Nagoya University,therapeutic,Interventional study
NCT02718859,Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"Fuda Cancer Hospital, Guangzhou",therapeutic,Interventional study
NCT02720666,K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability,INTERVENTIONAL,PHASE1,COMPLETED,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",therapeutic,Interventional study
NCT02737228,Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,UNKNOWN,"CrystalGenomics, Inc.",therapeutic,Interventional study
NCT02743975,Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,TERMINATED,University Medical Center Groningen,therapeutic,Interventional study
NCT02745847,Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Changhai Hospital,therapeutic,Interventional study
NCT02749136,Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Asan Medical Center,therapeutic,Interventional study
NCT02757859,High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery,INTERVENTIONAL,NA,RECRUITING,Sidney Kimmel Cancer Center at Thomas Jefferson University,therapeutic,Interventional study
NCT02767557,Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,COMPLETED,Herlev Hospital,therapeutic,Interventional study
NCT02775695,Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Medical College of Wisconsin,therapeutic,Interventional study
NCT02775786,Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,NA,COMPLETED,Columbia University,therapeutic,Interventional study
NCT02812992,Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients,INTERVENTIONAL,PHASE4,COMPLETED,AIO-Studien-gGmbH,therapeutic,Interventional study
NCT02818829,Biological and Clinical Database for Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,"University Hospital, Toulouse",other,Does not match therapeutic or biomarker criteria
NCT02818907,Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable,INTERVENTIONAL,NA,COMPLETED,Centre Hospitalier Universitaire de Besancon,therapeutic,Interventional study
NCT02827201,FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine,INTERVENTIONAL,PHASE2,COMPLETED,Federation Francophone de Cancerologie Digestive,therapeutic,Interventional study
NCT02839343,Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Alliance for Clinical Trials in Oncology,therapeutic,Interventional study
NCT02843945,Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source,INTERVENTIONAL,PHASE1,RECRUITING,CivaTech Oncology,therapeutic,Interventional study
NCT02850874,HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,WITHDRAWN,Wake Forest University Health Sciences,therapeutic,Interventional study
NCT02851381,"Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer",INTERVENTIONAL,NA,WITHDRAWN,Jonsson Comprehensive Cancer Center,therapeutic,Interventional study
NCT02858141,Onco-geriatric Database of Patients With Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Institut Paoli-Calmettes,other,Does not match therapeutic or biomarker criteria
NCT02863367,A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Tianjin Medical University Cancer Institute and Hospital,therapeutic,Interventional study
NCT02869802,Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis,OBSERVATIONAL,Unknown,RECRUITING,British Columbia Cancer Agency,biomarker,Biomarker or molecular study
NCT02873598,A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"University of Colorado, Denver",therapeutic,Interventional study
NCT02886247,Pancreatic Cancer Registry: For Any Person With a Personal or Family History,OBSERVATIONAL,Unknown,RECRUITING,Johns Hopkins University,other,Does not match therapeutic or biomarker criteria
NCT02892305,Hepatic Resection for Metastatic Pancreatic Cancer,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Duke University,biomarker,Biomarker or molecular study
NCT02894944,Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Seoul National University Hospital,therapeutic,Interventional study
NCT02896803,Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Instituto do Cancer do Estado de São Paulo,therapeutic,Interventional study
NCT02896907,Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery,INTERVENTIONAL,EARLY_PHASE1,COMPLETED,Sidney Kimmel Cancer Center at Thomas Jefferson University,therapeutic,Interventional study
NCT02896946,Diffusion MRI for Pancreatic Adenocarcinoma,INTERVENTIONAL,NA,COMPLETED,Hospices Civils de Lyon,therapeutic,Interventional study
NCT02898649,Safety and Efficacy of Irreversible Electroporation for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Yonsei University,therapeutic,Interventional study
NCT02900677,Developing Prehabilitation Program in Patients With Operable Pancreatic Cancer Perioperatively and Following Surgery,INTERVENTIONAL,NA,UNKNOWN,National Taiwan University Hospital,therapeutic,Interventional study
NCT02905578,A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1),INTERVENTIONAL,PHASE2,COMPLETED,Joseph J. Cullen,therapeutic,Interventional study
NCT02910882,"PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer",INTERVENTIONAL,PHASE2,TERMINATED,Scripps Health,therapeutic,Interventional study
NCT02919787,Nordic Pancreatic Cancer Trial (NorPACT) - 1,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Oslo University Hospital,therapeutic,Interventional study
NCT02921022,"Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma",INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT02921737,TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003),INTERVENTIONAL,PHASE2,TERMINATED,University of Florida,therapeutic,Interventional study
NCT02926040,Quality of Life After in Situ IRE in Locally Advanced Pancreatic Cancer,OBSERVATIONAL,Unknown,TERMINATED,"Insel Gruppe AG, University Hospital Bern",other,Does not match therapeutic or biomarker criteria
NCT02929797,Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,UNKNOWN,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",therapeutic,Interventional study
NCT02930902,Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery,INTERVENTIONAL,PHASE1,COMPLETED,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT02945267,Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE4,UNKNOWN,Chinese PLA General Hospital,therapeutic,Interventional study
NCT02959879,Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,UNKNOWN,"University Hospital, Rouen",therapeutic,Interventional study
NCT02967770,Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,WITHDRAWN,Georgetown University,therapeutic,Interventional study
NCT02973217,Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,Clinical Laserthermia Systems AB,therapeutic,Interventional study
NCT02974764,Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,COMPLETED,Johns Hopkins University,biomarker,Biomarker or molecular study
NCT02977702,Sarcopenia is an Independent Prognostic Factor for Overall Survival in Patients With Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,COMPLETED,Institut de Cancérologie de Lorraine,biomarker,Biomarker or molecular study
NCT02979483,Management of Symptomatic Advanced Pancreatic Adenocarcinoma,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,GERCOR - Multidisciplinary Oncology Cooperative Group,therapeutic,Interventional study
NCT02985125,LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy,INTERVENTIONAL,PHASE1,UNKNOWN,Georgetown University,therapeutic,Interventional study
NCT02993731,A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE3,COMPLETED,"Sumitomo Pharma America, Inc.",therapeutic,Interventional study
NCT03001518,Immunologic Signatures Following Surgery for Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Duke University,biomarker,Biomarker or molecular study
NCT03003078,A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane,INTERVENTIONAL,NA,COMPLETED,OncoSil Medical Limited,therapeutic,Interventional study
NCT03033927,Predicting Effective Therapy in Pancreatic Cancer,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,biomarker,Biomarker or molecular study
NCT03040986,Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations,INTERVENTIONAL,PHASE2,COMPLETED,National Cancer Institute (NCI),therapeutic,Interventional study
NCT03042442,"Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy",OBSERVATIONAL,Unknown,COMPLETED,Iuliu Hatieganu University of Medicine and Pharmacy,biomarker,Biomarker or molecular study
NCT03069599,Immune Response After Pancreatic Cancer Treatment,OBSERVATIONAL,Unknown,TERMINATED,"Insel Gruppe AG, University Hospital Bern",other,Does not match therapeutic or biomarker criteria
NCT03069664,Palliative Pancreatic Duct Stenting in Patients With Inoperable Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Helsinki University Central Hospital,therapeutic,Interventional study
NCT03073785,Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,University of Nebraska,therapeutic,Interventional study
NCT03076502,"The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer",OBSERVATIONAL,Unknown,UNKNOWN,RenJi Hospital,biomarker,Biomarker or molecular study
NCT03077685,Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,COMPLETED,"NanOlogy, LLC",therapeutic,Interventional study
NCT03086369,A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Eli Lilly and Company,therapeutic,Interventional study
NCT03086642,Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"Karie D. Runcie, MD",therapeutic,Interventional study
NCT03105921,Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma,INTERVENTIONAL,NA,COMPLETED,Poitiers University Hospital,therapeutic,Interventional study
NCT03117556,Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,WITHDRAWN,University of Louisville,therapeutic,Interventional study
NCT03117920,"A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,Minneamrita Therapeutics LLC,therapeutic,Interventional study
NCT03136406,QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,INTERVENTIONAL,PHASE1,TERMINATED,"ImmunityBio, Inc.",therapeutic,Interventional study
NCT03138720,Pre-operative Treatment for Patients With Untreated Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,HonorHealth Research Institute,therapeutic,Interventional study
NCT03158779,Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Istituto Clinico Humanitas,therapeutic,Interventional study
NCT03159819,Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma,INTERVENTIONAL,NA,UNKNOWN,Changhai Hospital,therapeutic,Interventional study
NCT03165591,Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer,INTERVENTIONAL,PHASE1,UNKNOWN,Immunitor LLC,therapeutic,Interventional study
NCT03180437,Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"Fuda Cancer Hospital, Guangzhou",therapeutic,Interventional study
NCT03187587,Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer,INTERVENTIONAL,NA,TERMINATED,Clinical Laserthermia Systems AB,therapeutic,Interventional study
NCT03187951,PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT03192462,TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Baylor College of Medicine,therapeutic,Interventional study
NCT03199144,Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,WITHDRAWN,"Centre Francois Baclesse, Luxembourg",therapeutic,Interventional study
NCT03207724,Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia,INTERVENTIONAL,PHASE1,COMPLETED,"Andrew Hendifar, MD",therapeutic,Interventional study
NCT03215459,Cardiopulmonary Exercise Testing: An Assessment of Patients Fitness for Palliative Chemotherapy for Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,The Clatterbridge Cancer Centre NHS Foundation Trust,other,Does not match therapeutic or biomarker criteria
NCT03239184,Bioinformation Therapy for Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"Fuda Cancer Hospital, Guangzhou",therapeutic,Interventional study
NCT03256201,Exercise and Nutrition to Improve Pancreatic Cancer Outcomes,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,University of Oklahoma,therapeutic,Interventional study
NCT03264404,Azacitidine and Pembrolizumab in Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Susan E. Bates,therapeutic,Interventional study
NCT03266757,Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,COMPLETED,Hellenic Society of Medical Oncology,biomarker,Biomarker or molecular study
NCT03269526,"BATs Treatment for Pancreatic Cancer, Phase Ib/II",INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,University of Virginia,therapeutic,Interventional study
NCT03278015,Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,UNKNOWN,Chinese PLA General Hospital,therapeutic,Interventional study
NCT03281382,Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Henry Ford Health System,therapeutic,Interventional study
NCT03301805,"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer",INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Rgene Corporation,therapeutic,Interventional study
NCT03307148,Stromal TARgeting for PAncreatic Cancer (STAR_PAC),INTERVENTIONAL,PHASE1,COMPLETED,Barts & The London NHS Trust,therapeutic,Interventional study
NCT03307564,Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT03311776,"BIOmarkers in Patients With Pancreatic Cancer (""BIOPAC"")",OBSERVATIONAL,Unknown,RECRUITING,"Inna Chen, MD",biomarker,Biomarker or molecular study
NCT03316326,"S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE2,UNKNOWN,National Taiwan University Hospital,therapeutic,Interventional study
NCT03336216,A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Bristol-Myers Squibb,therapeutic,Interventional study
NCT03344172,Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,"Nathan Bahary, MD",therapeutic,Interventional study
NCT03377491,"Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)",INTERVENTIONAL,PHASE3,COMPLETED,NovoCure Ltd.,therapeutic,Interventional study
NCT03387098,QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,INTERVENTIONAL,PHASE1,TERMINATED,"ImmunityBio, Inc.",therapeutic,Interventional study
NCT03392571,Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,WITHDRAWN,Pancreatic Cancer Research Team,therapeutic,Interventional study
NCT03401827,The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE4,UNKNOWN,Seoul National University Hospital,therapeutic,Interventional study
NCT03412799,Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"Panbela Therapeutics, Inc.",therapeutic,Interventional study
NCT03432676,Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,WITHDRAWN,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT03447691,Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery,INTERVENTIONAL,NA,UNKNOWN,Yonsei University,therapeutic,Interventional study
NCT03468335,2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy,INTERVENTIONAL,PHASE3,COMPLETED,AIO-Studien-gGmbH,therapeutic,Interventional study
NCT03469375,Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,"Second Affiliated Hospital, School of Medicine, Zhejiang University",other,Does not match therapeutic or biomarker criteria
NCT03469726,Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Radboud University Medical Center,therapeutic,Interventional study
NCT03470948,Surgical Apgar Score After Whipple Procedure in Pancreatic Cancer Patients,OBSERVATIONAL,Unknown,TERMINATED,Tata Memorial Hospital,other,Does not match therapeutic or biomarker criteria
NCT03472716,The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC),OBSERVATIONAL,Unknown,UNKNOWN,Centre Leon Berard,biomarker,Biomarker or molecular study
NCT03483038,A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,University of Florida,therapeutic,Interventional study
NCT03490604,Ambulatory Measurement of Physical Activity in Pancreatic Cancer Patients,OBSERVATIONAL,Unknown,COMPLETED,Centre Hospitalier Universitaire Dijon,biomarker,Biomarker or molecular study
NCT03492164,In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,TERMINATED,Abramson Cancer Center at Penn Medicine,therapeutic,Interventional study
NCT03496662,BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC),INTERVENTIONAL,PHASE1,COMPLETED,Washington University School of Medicine,therapeutic,Interventional study
NCT03497819,Autologous CARTmeso/19 Against Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,UNKNOWN,First Affiliated Hospital of Wenzhou Medical University,therapeutic,Interventional study
NCT03498326,Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,"Second Affiliated Hospital, School of Medicine, Zhejiang University",therapeutic,Interventional study
NCT03502343,Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Yonsei University,therapeutic,Interventional study
NCT03505229,Span-C-SBRT for Pancreatic Cancer,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,Royal North Shore Hospital,therapeutic,Interventional study
NCT03509298,Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,WITHDRAWN,"Fuda Cancer Hospital, Guangzhou",therapeutic,Interventional study
NCT03512756,A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,"Tyme, Inc",therapeutic,Interventional study
NCT03520790,Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,Dana-Farber Cancer Institute,therapeutic,Interventional study
NCT03523312,Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT03531125,Gene Expression in Pancreatic Cancer,OBSERVATIONAL,Unknown,TERMINATED,University of Oxford,biomarker,Biomarker or molecular study
NCT03536208,Biological Effect of Warfarin on Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,WITHDRAWN,University of Texas Southwestern Medical Center,therapeutic,Interventional study
NCT03541486,A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,WITHDRAWN,"Joseph J. Cullen, MD, FACS",therapeutic,Interventional study
NCT03559348,Locally Advanced or Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,COMPLETED,"National Health Research Institutes, Taiwan",therapeutic,Interventional study
NCT03572400,Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Do-Youn Oh,therapeutic,Interventional study
NCT03579836,Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer,INTERVENTIONAL,PHASE1,RECRUITING,BeyondBio Inc.,therapeutic,Interventional study
NCT03585062,Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Zhejiang Provincial People's Hospital,therapeutic,Interventional study
NCT03586869,QUILT-3.080: NANT Pancreatic Cancer Vaccine,INTERVENTIONAL,PHASE1,TERMINATED,"ImmunityBio, Inc.",therapeutic,Interventional study
NCT03599362,"Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer",INTERVENTIONAL,PHASE2,TERMINATED,NYU Langone Health,therapeutic,Interventional study
NCT03600623,Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,TERMINATED,University of Alabama at Birmingham,therapeutic,Interventional study
NCT03616431,Pancreatic Cancer Dietary Assessment Study,OBSERVATIONAL,Unknown,COMPLETED,The Christie NHS Foundation Trust,other,Does not match therapeutic or biomarker criteria
NCT03621644,Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,Viewray Inc.,therapeutic,Interventional study
NCT03632850,Web-based Treatment Information Tool for People With Advanced Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Bournemouth University,other,Does not match therapeutic or biomarker criteria
NCT03633734,Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,UNKNOWN,"Second Affiliated Hospital, School of Medicine, Zhejiang University",therapeutic,Interventional study
NCT03649035,Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE3,WITHDRAWN,Istituto Clinico Humanitas,therapeutic,Interventional study
NCT03662035,Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Changzhou No.2 People's Hospital,therapeutic,Interventional study
NCT03662412,Study of Sirolimus in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,UNKNOWN,"Second Affiliated Hospital, School of Medicine, Zhejiang University",therapeutic,Interventional study
NCT03666832,"Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel",INTERVENTIONAL,PHASE1,UNKNOWN,Joon Oh Park,therapeutic,Interventional study
NCT03687853,Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery,INTERVENTIONAL,NA,UNKNOWN,Peking University Third Hospital,therapeutic,Interventional study
NCT03693677,"First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI",INTERVENTIONAL,PHASE2,COMPLETED,Federation Francophone de Cancerologie Digestive,therapeutic,Interventional study
NCT03697239,High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,WITHDRAWN,Hitendra Patel,therapeutic,Interventional study
NCT03703089,Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology,INTERVENTIONAL,PHASE1,UNKNOWN,Benaroya Research Institute,therapeutic,Interventional study
NCT03714542,Prospective Evaluation of the Role of MRI in the Perioperative Management of Pancreas Adenocarcinomas,INTERVENTIONAL,NA,COMPLETED,University of Lausanne Hospitals,therapeutic,Interventional study
NCT03716531,Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,Massachusetts General Hospital,therapeutic,Interventional study
NCT03716596,SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients,INTERVENTIONAL,PHASE1,TERMINATED,"Second Affiliated Hospital, School of Medicine, Zhejiang University",therapeutic,Interventional study
NCT03723915,Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Northwestern University,therapeutic,Interventional study
NCT03724435,Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry,OBSERVATIONAL,Unknown,TERMINATED,Focused Ultrasound Foundation,other,Does not match therapeutic or biomarker criteria
NCT03727880,Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Lei Zheng,therapeutic,Interventional study
NCT03750669,Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,"Second Affiliated Hospital, School of Medicine, Zhejiang University",therapeutic,Interventional study
NCT03766295,Masitinib Plus Gemcitabine in Pancreatic Cancer,INTERVENTIONAL,PHASE3,COMPLETED,AB Science,therapeutic,Interventional study
NCT03767582,Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.,INTERVENTIONAL,PHASE1,COMPLETED,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT03770247,Intraoperative Versus CT Guided Celiac Plexus Neurolysis in Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,Mansoura University,therapeutic,Interventional study
NCT03772756,EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,NA,COMPLETED,First People's Hospital of Hangzhou,therapeutic,Interventional study
NCT03777462,Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1,INTERVENTIONAL,PHASE2,UNKNOWN,Changhai Hospital,therapeutic,Interventional study
NCT03791073,New Biomarkers in Pancreatic Cancer Using EXPEL Concept,OBSERVATIONAL,Unknown,UNKNOWN,"University Hospital, Montpellier",biomarker,Biomarker or molecular study
NCT03792932,Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Fudan University,therapeutic,Interventional study
NCT03806309,"OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC",INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,GERCOR - Multidisciplinary Oncology Cooperative Group,therapeutic,Interventional study
NCT03816163,A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,"Astellas Pharma Global Development, Inc.",therapeutic,Interventional study
NCT03822936,Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma,INTERVENTIONAL,PHASE2,TERMINATED,CNAO National Center of Oncological Hadrontherapy,therapeutic,Interventional study
NCT03838029,Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery,INTERVENTIONAL,PHASE2,RECRUITING,Assaf-Harofeh Medical Center,therapeutic,Interventional study
NCT03840460,A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers,OBSERVATIONAL,Unknown,UNKNOWN,Royal Marsden NHS Foundation Trust,biomarker,Biomarker or molecular study
NCT03848182,Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Albert Einstein College of Medicine,therapeutic,Interventional study
NCT03851237,CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy,INTERVENTIONAL,PHASE1,COMPLETED,Washington University School of Medicine,therapeutic,Interventional study
NCT03856658,Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Corewell Health West,therapeutic,Interventional study
NCT03859869,A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI),INTERVENTIONAL,PHASE4,TERMINATED,AbbVie,therapeutic,Interventional study
NCT03882866,Iodine-125 Seed Implantation Therapy for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Ruijin Hospital,therapeutic,Interventional study
NCT03886298,Radiofrequency Splanchnic Denervation Versus Retrocrural Neurolytic Celiac Block for Pancreatic Cancer Pain,INTERVENTIONAL,NA,UNKNOWN,Assiut University,therapeutic,Interventional study
NCT03886571,U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Hoag Memorial Hospital Presbyterian,biomarker,Biomarker or molecular study
NCT03890198,A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,EARLY_PHASE1,TERMINATED,First Affiliated Hospital Xi'an Jiaotong University,therapeutic,Interventional study
NCT03895177,Evaluation of Resectability of Pancreatic Cancer Using Low kVp CT,INTERVENTIONAL,NA,UNKNOWN,Seoul National University Hospital,therapeutic,Interventional study
NCT03899649,A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,"Angiodynamics, Inc.",other,Does not match therapeutic or biomarker criteria
NCT03908333,High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,WITHDRAWN,Medical College of Wisconsin,therapeutic,Interventional study
NCT03910387,Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Emory University,therapeutic,Interventional study
NCT03937453,A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus,OBSERVATIONAL,Unknown,RECRUITING,Nuvance Health,other,Early detection / screening study
NCT03940027,EUS-guided Celiac Plexus Neurolysis for the Treatment of Abdominal Pain in Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Changhai Hospital,therapeutic,Interventional study
NCT03943667,Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE3,COMPLETED,UNICANCER,therapeutic,Interventional study
NCT03957135,Laparoscopic Versus Open Distal Pancreatectomy for Pancreatic Cancer: a Multicenter Randomized Controlled Trial,INTERVENTIONAL,NA,UNKNOWN,Seoul National University Hospital,therapeutic,Interventional study
NCT03959150,Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Ruijin Hospital,therapeutic,Interventional study
NCT03970252,Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,COMPLETED,Jonsson Comprehensive Cancer Center,therapeutic,Interventional study
NCT03977233,Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,UNC Lineberger Comprehensive Cancer Center,therapeutic,Interventional study
NCT03982446,Germline Mutations in Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,COMPLETED,Hellenic Cooperative Oncology Group,biomarker,Biomarker or molecular study
NCT03983057,Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer,INTERVENTIONAL,PHASE3,UNKNOWN,Zhejiang University,therapeutic,Interventional study
NCT03986294,Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),therapeutic,Interventional study
NCT03989310,"An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE1,UNKNOWN,Chinese PLA General Hospital,therapeutic,Interventional study
NCT04002479,Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,Alpha Tau Medical LTD.,therapeutic,Interventional study
NCT04024358,A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Massimo Falconi,other,Does not match therapeutic or biomarker criteria
NCT04049461,Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Nanjing Medical University,other,Does not match therapeutic or biomarker criteria
NCT04054362,Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE2,COMPLETED,Barts & The London NHS Trust,therapeutic,Interventional study
NCT04083235,"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment",INTERVENTIONAL,PHASE3,COMPLETED,Ipsen,therapeutic,Interventional study
NCT04083651,A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,WITHDRAWN,"Bausch Health Americas, Inc.",therapeutic,Interventional study
NCT04084496,mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,RECRUITING,Sun Yat-sen University,therapeutic,Interventional study
NCT04087889,Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer,EXPANDED_ACCESS,Unknown,NO_LONGER_AVAILABLE,Hope Biosciences LLC,other,Does not match therapeutic or biomarker criteria
NCT04091295,"BLESSED: Expanded Access for DNG64 for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast",EXPANDED_ACCESS,Unknown,AVAILABLE,Aveni Foundation,other,Does not match therapeutic or biomarker criteria
NCT04095195,Registry of Subjects at Risk of Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,Associazione Italiana per lo Studio del Pancreas,biomarker,Biomarker or molecular study
NCT04101929,"Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen",INTERVENTIONAL,PHASE2,UNKNOWN,Fudan University,therapeutic,Interventional study
NCT04109495,Usefulness of Smartphone Application for Improving Nutritional Status of Pancreatic Cancer Patients,INTERVENTIONAL,NA,COMPLETED,Yonsei University,therapeutic,Interventional study
NCT04112836,Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Moscow Clinical Scientific Center,biomarker,Biomarker or molecular study
NCT04115163,Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Anne Noonan,therapeutic,Interventional study
NCT04119362,"PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer",OBSERVATIONAL,Unknown,COMPLETED,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,other,Does not match therapeutic or biomarker criteria
NCT04123574,A Pilot Study of BXCL701 in Patients With Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,WITHDRAWN,BioXcel Therapeutics Inc,therapeutic,Interventional study
NCT04133155,Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Asan Medical Center,biomarker,Biomarker or molecular study
NCT04134468,MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE2,WITHDRAWN,Abramson Cancer Center at Penn Medicine,therapeutic,Interventional study
NCT04136522,Usefulness of the Artery First Approach in Pancreatic Cancer Surgery,INTERVENTIONAL,NA,UNKNOWN,Asan Medical Center,therapeutic,Interventional study
NCT04143152,Pancreatic Cancer Biomarker Study,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Van Andel Research Institute,biomarker,Biomarker or molecular study
NCT04151719,An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,WITHDRAWN,"Bausch Health Americas, Inc.",therapeutic,Interventional study
NCT04161417,Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,Judith Dixon-Hughes,therapeutic,Interventional study
NCT04176952,PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Judith Dixon-Hughes,therapeutic,Interventional study
NCT04196816,Surgery for Pancreatic Cancer With Oligo-Metastasis,OBSERVATIONAL,Unknown,COMPLETED,"University Hospital, Montpellier",other,Does not match therapeutic or biomarker criteria
NCT04216758,Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Fudan University,therapeutic,Interventional study
NCT04228601,A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"Jiangsu HengRui Medicine Co., Ltd.",therapeutic,Interventional study
NCT04239001,Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.",therapeutic,Interventional study
NCT04241276,A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Queen Mary University of London,therapeutic,Interventional study
NCT04246203,Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Ludwig-Maximilians - University of Munich,biomarker,Biomarker or molecular study
NCT04257448,Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,GWT-TUD GmbH,therapeutic,Interventional study
NCT04257955,COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer,OBSERVATIONAL,Unknown,COMPLETED,IRCCS San Raffaele,other,Does not match therapeutic or biomarker criteria
NCT04258150,"Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE2,TERMINATED,Herlev Hospital,therapeutic,Interventional study
NCT04263948,Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Plateform,INTERVENTIONAL,NA,COMPLETED,Ramsay Générale de Santé,therapeutic,Interventional study
NCT04281290,Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study),INTERVENTIONAL,PHASE1,TERMINATED,University Medical Centre Ljubljana,therapeutic,Interventional study
NCT04293497,Development of a New Immunochemistry Method Using Antibodies of Proteins Related Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,Gangnam Severance Hospital,therapeutic,Interventional study
NCT04300114,A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy,INTERVENTIONAL,PHASE3,TERMINATED,"Jiangsu HengRui Medicine Co., Ltd.",therapeutic,Interventional study
NCT04306861,Novel MRI Techniques for Pancreatic Cancer,OBSERVATIONAL,Unknown,WITHDRAWN,Beth Israel Deaconess Medical Center,biomarker,Biomarker or molecular study
NCT04310111,EUS-RFA for Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,First People's Hospital of Hangzhou,therapeutic,Interventional study
NCT04323917,Detection of High Expression Levels of EMT-Transcription Factor mRNAs in Patients With Pancreatic Cancer and Their Diagnostic Potential,OBSERVATIONAL,Unknown,UNKNOWN,Istituto Clinico Humanitas,biomarker,Biomarker or molecular study
NCT04340141,Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer,INTERVENTIONAL,PHASE3,ACTIVE_NOT_RECRUITING,Alliance for Clinical Trials in Oncology,therapeutic,Interventional study
NCT04361162,Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Massachusetts General Hospital,therapeutic,Interventional study
NCT04371224,NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Seoul National University Hospital,therapeutic,Interventional study
NCT04377048,Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,National Taiwan University Hospital,therapeutic,Interventional study
NCT04379960,Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines,OBSERVATIONAL,Unknown,COMPLETED,Queen Mary University of London,other,Does not match therapeutic or biomarker criteria
NCT04381130,A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,"Everfront Biotech Co., Ltd.",therapeutic,Interventional study
NCT04386057,LY3214996 +/- HCQ in Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,"Kimberly Perez, MD",therapeutic,Interventional study
NCT04387071,CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma,INTERVENTIONAL,PHASE1,TERMINATED,University of Southern California,therapeutic,Interventional study
NCT04390243,Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation,INTERVENTIONAL,PHASE2,TERMINATED,Academic and Community Cancer Research United,therapeutic,Interventional study
NCT04409002,Niraparib + Dostarlimab + RT in Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Massachusetts General Hospital,therapeutic,Interventional study
NCT04425876,A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE1,UNKNOWN,"Jiangsu HengRui Medicine Co., Ltd.",therapeutic,Interventional study
NCT04427761,A Study of the Life Changes Experienced by Patients With Pancreatic Cancer,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,other,Does not match therapeutic or biomarker criteria
NCT04436679,INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors,OBSERVATIONAL,Unknown,COMPLETED,"University Hospital, Lille",other,Does not match therapeutic or biomarker criteria
NCT04447092,Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Seoul National University Hospital,therapeutic,Interventional study
NCT04476537,RNA Precision Oncology in Advanced Pancreatic Cancer,INTERVENTIONAL,NA,TERMINATED,Columbia University,therapeutic,Interventional study
NCT04481204,"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study",INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT04493060,Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Mayo Clinic,therapeutic,Interventional study
NCT04525209,Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma,OBSERVATIONAL,Unknown,UNKNOWN,Ruijin Hospital,biomarker,Biomarker or molecular study
NCT04536077,Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,TERMINATED,Washington University School of Medicine,therapeutic,Interventional study
NCT04539808,"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer",INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,OHSU Knight Cancer Institute,therapeutic,Interventional study
NCT04548752,"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations",INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,National Cancer Institute (NCI),therapeutic,Interventional study
NCT04549064,Biomarkers of Pancreatic Cancer and New Way to Detection,OBSERVATIONAL,Unknown,UNKNOWN,First Affiliated Hospital Xi'an Jiaotong University,biomarker,Biomarker or molecular study
NCT04575363,RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,CHU de Reims,therapeutic,Interventional study
NCT04581876,The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Fudan University,therapeutic,Interventional study
NCT04588025,Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response,INTERVENTIONAL,NA,RECRUITING,University of Alabama at Birmingham,therapeutic,Interventional study
NCT04592861,Carbon Ion RT for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,TERMINATED,Albert Einstein College of Medicine,therapeutic,Interventional study
NCT04605237,Pancreatic Cancer Recurrence in the Netherlands,OBSERVATIONAL,Unknown,UNKNOWN,UMC Utrecht,other,Does not match therapeutic or biomarker criteria
NCT04616131,Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Central DuPage Hospital,biomarker,Biomarker or molecular study
NCT04617067,"Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE2,COMPLETED,Cancer Trials Ireland,therapeutic,Interventional study
NCT04631445,Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,Translational Drug Development,therapeutic,Interventional study
NCT04632303,Early Palliative Care for Patients With Advanced Pancreatic Cancer.,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,"Inna Chen, MD",therapeutic,Interventional study
NCT04636788,Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Huazhong University of Science and Technology,therapeutic,Interventional study
NCT04637698,OH2 Oncolytic Viral Therapy in Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,"Binhui Biopharmaceutical Co., Ltd.",therapeutic,Interventional study
NCT04665947,First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,RECRUITING,"University of California, Davis",therapeutic,Interventional study
NCT04683497,"CE-IOUS for Patients With Pancreatic Cancer Undergoing Surgery: A Prospective, Proof-of-concept Trial",INTERVENTIONAL,NA,UNKNOWN,University of Thessaly,therapeutic,Interventional study
NCT04692740,Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial),INTERVENTIONAL,PHASE2,UNKNOWN,Michele Reni,therapeutic,Interventional study
NCT04698915,Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,"Galera Therapeutics, Inc.",therapeutic,Interventional study
NCT04723030,The Transformation of Locally Advanced Pancreatic Cancer.,INTERVENTIONAL,PHASE2,UNKNOWN,Peking University,therapeutic,Interventional study
NCT04726956,A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC,OBSERVATIONAL,Unknown,COMPLETED,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",other,Does not match therapeutic or biomarker criteria
NCT04736043,Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid,OBSERVATIONAL,Unknown,UNKNOWN,Samsung Medical Center,biomarker,Biomarker or molecular study
NCT04752696,"Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma",INTERVENTIONAL,PHASE2,COMPLETED,Cardiff Oncology,therapeutic,Interventional study
NCT04765410,The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,UNKNOWN,Carol Davila University of Medicine and Pharmacy,biomarker,Biomarker or molecular study
NCT04777604,Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Organoid,OBSERVATIONAL,Unknown,UNKNOWN,Samsung Medical Center,biomarker,Biomarker or molecular study
NCT04787991,Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,COMPLETED,"Cancer Insight, LLC",therapeutic,Interventional study
NCT04789486,Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer,INTERVENTIONAL,PHASE1,RECRUITING,Dana-Farber Cancer Institute,therapeutic,Interventional study
NCT04789980,Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY,OBSERVATIONAL,Unknown,COMPLETED,"Boryung Pharmaceutical Co., Ltd",other,Does not match therapeutic or biomarker criteria
NCT04793633,Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer,OBSERVATIONAL,Unknown,ENROLLING_BY_INVITATION,"Adenocyte, LLC",biomarker,Biomarker or molecular study
NCT04796948,A Study of Irinotecan Liposome in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"Jiangsu HengRui Medicine Co., Ltd.",therapeutic,Interventional study
NCT04814485,Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Tianjin Medical University Cancer Institute and Hospital,therapeutic,Interventional study
NCT04820179,"Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer",INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,University of Arizona,therapeutic,Interventional study
NCT04821219,Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids,INTERVENTIONAL,NA,WITHDRAWN,Mayo Clinic,therapeutic,Interventional study
NCT04821284,Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer,INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,Flemming Forsberg,therapeutic,Interventional study
NCT04834505,To Differentiate Focal Autoimmune Pancreatitis From Pancreatic Cancer by Endoscopic Ultrasound,OBSERVATIONAL,Unknown,COMPLETED,Peking Union Medical College Hospital,other,Does not match therapeutic or biomarker criteria
NCT04837118,"Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study",INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT04837833,An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT04844970,Anamorelin Study for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Lahey Clinic,therapeutic,Interventional study
NCT04858009,Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis,INTERVENTIONAL,PHASE2,RECRUITING,Mayo Clinic,therapeutic,Interventional study
NCT04883775,Study of a New Technique for Imaging Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT04887805,Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,City of Hope Medical Center,therapeutic,Interventional study
NCT04894643,"Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer",INTERVENTIONAL,NA,RECRUITING,EBG MedAustron GmbH,therapeutic,Interventional study
NCT04902352,The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,University Hospital Birmingham NHS Foundation Trust,therapeutic,Interventional study
NCT04930991,High Dose Omeprazole in Patients With Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,RECRUITING,University of Oklahoma,therapeutic,Interventional study
NCT04931381,Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,UNKNOWN,Changhai Hospital,therapeutic,Interventional study
NCT04940286,"Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer",INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT04953962,Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,CanBas Co. Ltd.,therapeutic,Interventional study
NCT04966143,Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,UNKNOWN,"Shanghai Longyao Biotechnology Inc., Ltd.",therapeutic,Interventional study
NCT04969731,Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE3,RECRUITING,GC Cell Corporation,therapeutic,Interventional study
NCT04975217,Fecal Microbial Transplants for the Treatment of Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,RECRUITING,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT04975516,Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Mayo Clinic,therapeutic,Interventional study
NCT04977596,Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,"Second Affiliated Hospital, School of Medicine, Zhejiang University",other,Does not match therapeutic or biomarker criteria
NCT04993846,Pancreatic Cancer and Oral Microbiome,OBSERVATIONAL,Unknown,UNKNOWN,Azienda Ospedaliera Universitaria Integrata Verona,other,Does not match therapeutic or biomarker criteria
NCT05013216,Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer,INTERVENTIONAL,PHASE1,RECRUITING,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT05023291,Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Pancreatic Adenocarcinoma,INTERVENTIONAL,NA,TERMINATED,"University Hospital, Ghent",therapeutic,Interventional study
NCT05025371,The Role of Systemic Immuno-inflammatory Factors in Resectable Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,COMPLETED,Iuliu Hatieganu University of Medicine and Pharmacy,biomarker,Biomarker or molecular study
NCT05026905,A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,"National Health Research Institutes, Taiwan",therapeutic,Interventional study
NCT05034627,Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,OHSU Knight Cancer Institute,therapeutic,Interventional study
NCT05048524,Peri-operative SLOG for Localized Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,"National Health Research Institutes, Taiwan",therapeutic,Interventional study
NCT05055323,"A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer",INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,Thomas Jefferson University,therapeutic,Interventional study
NCT05077800,FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,"Colin D. Weekes, M.D., PhD",therapeutic,Interventional study
NCT05086250,Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,RECRUITING,Cedars-Sinai Medical Center,therapeutic,Interventional study
NCT05093231,Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Cambridge University Hospitals NHS Foundation Trust,therapeutic,Interventional study
NCT05098197,A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital),INTERVENTIONAL,EARLY_PHASE1,RECRUITING,Shanghai Juncell Therapeutics,therapeutic,Interventional study
NCT05100329,A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",therapeutic,Interventional study
NCT05102721,Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,Vaccinex Inc.,therapeutic,Interventional study
NCT05114213,MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC,INTERVENTIONAL,PHASE2,TERMINATED,Ludwig-Maximilians - University of Munich,therapeutic,Interventional study
NCT05132244,Monitoring and Managing Glucose Levels in People With Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,British Columbia Cancer Agency,therapeutic,Interventional study
NCT05132504,Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Baylor College of Medicine,therapeutic,Interventional study
NCT05138159,A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen,INTERVENTIONAL,PHASE2,UNKNOWN,Fudan University,therapeutic,Interventional study
NCT05138302,A Clinical Study of BRCA and DNA Damage Repair Genes in Blood Samples of Chinese Pancreatic Cancer Patients,OBSERVATIONAL,Unknown,UNKNOWN,RenJi Hospital,other,Does not match therapeutic or biomarker criteria
NCT05147168,Quality of Life of Pancreatic Cancer Patients:Psychometric Validation of Chinese Version in Taiwan,OBSERVATIONAL,Unknown,UNKNOWN,"Taipei Veterans General Hospital, Taiwan",other,Does not match therapeutic or biomarker criteria
NCT05168254,Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Ruijin Hospital,biomarker,Biomarker or molecular study
NCT05181488,Intraoperative Radiation Therapy for Resectable Pancreatic Cancer,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,Yona Cho,therapeutic,Interventional study
NCT05187416,Correlation Between Elastic Modulus of Ultrasonic Shear Wave and Tumor Stromal Component in Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Xijing Hospital,other,Does not match therapeutic or biomarker criteria
NCT05188573,EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients,INTERVENTIONAL,NA,UNKNOWN,ClearNote Health,therapeutic,Interventional study
NCT05188586,New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED),INTERVENTIONAL,NA,TERMINATED,ClearNote Health,therapeutic,Interventional study
NCT05191498,Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,Radboud University Medical Center,therapeutic,Interventional study
NCT05218889,Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,RECRUITING,Chinese PLA General Hospital,therapeutic,Interventional study
NCT05222204,DDP ip Combined With AG in PDAC With Peritoneal Metastasis,INTERVENTIONAL,PHASE2,COMPLETED,Fudan University,therapeutic,Interventional study
NCT05239182,9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,TERMINATED,Anwaar Saeed,therapeutic,Interventional study
NCT05244174,Impact of Pancreatic Endoscopic Drainage on Exocrine Pancreatic Function in Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Hospital Clinico Universitario de Santiago,therapeutic,Interventional study
NCT05247164,EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,IRCCS San Raffaele,therapeutic,Interventional study
NCT05248750,"Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma",OBSERVATIONAL,Unknown,RECRUITING,Catholic University of the Sacred Heart,biomarker,Biomarker or molecular study
NCT05254171,Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,"Panbela Therapeutics, Inc.",therapeutic,Interventional study
NCT05257434,Postoperative Outcomes in Patients With Hepato-biliary-pancreatic Cancer According to inBody Test,OBSERVATIONAL,Unknown,RECRUITING,Kochi University,other,Does not match therapeutic or biomarker criteria
NCT05275062,Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma,INTERVENTIONAL,EARLY_PHASE1,UNKNOWN,"Beijing Immunochina Medical Science & Technology Co., Ltd.",therapeutic,Interventional study
NCT05277987,An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects,INTERVENTIONAL,EARLY_PHASE1,UNKNOWN,Shenzhen Fifth People's Hospital,therapeutic,Interventional study
NCT05303090,Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Fudan University,therapeutic,Interventional study
NCT05327582,"An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC",INTERVENTIONAL,PHASE1,UNKNOWN,Chinese PLA General Hospital,therapeutic,Interventional study
NCT05329597,Study on Umorestat Hydrogen Sulfate Capsule in Patients With Locally Advanced/Metastatic Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,other,Does not match therapeutic or biomarker criteria
NCT05346146,"A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.",INTERVENTIONAL,PHASE2,UNKNOWN,RenJi Hospital,therapeutic,Interventional study
NCT05351983,Patient-derived Organoids Drug Screen in Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,"Prof. Dr. med. Dres. h.c. Jan Schmidt, MME",therapeutic,Interventional study
NCT05355298,ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer,INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,Amplia Therapeutics Limited,therapeutic,Interventional study
NCT05356117,Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial,INTERVENTIONAL,NA,RECRUITING,Dana-Farber Cancer Institute,therapeutic,Interventional study
NCT05365893,PHL Treatment in Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,RECRUITING,Fox Chase Cancer Center,therapeutic,Interventional study
NCT05380414,Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients,INTERVENTIONAL,NA,RECRUITING,Centre Leon Berard,therapeutic,Interventional study
NCT05380557,ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing,OBSERVATIONAL,Unknown,TERMINATED,Invitae Corporation,biomarker,Biomarker or molecular study
NCT05400408,Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study,INTERVENTIONAL,NA,NOT_YET_RECRUITING,Scentech Medical Technologies Ltd,therapeutic,Interventional study
NCT05400681,Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Sonke Detlefsen,biomarker,Biomarker or molecular study
NCT05435053,Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,TERMINATED,Ismail Gögenur,therapeutic,Interventional study
NCT05441189,Precise Gene Signature for Predicting Outcomes in PDAC,OBSERVATIONAL,Unknown,COMPLETED,The Fourth Affiliated Hospital of Anhui Medical University,biomarker,Biomarker or molecular study
NCT05470166,Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity.,INTERVENTIONAL,NA,COMPLETED,Alexandria University,therapeutic,Interventional study
NCT05475366,Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign),INTERVENTIONAL,NA,RECRUITING,Institut Curie,therapeutic,Interventional study
NCT05481476,Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Sun Yat-sen University,therapeutic,Interventional study
NCT05482451,Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,ACTIVE_NOT_RECRUITING,China Medical University Hospital,therapeutic,Interventional study
NCT05483075,Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer,INTERVENTIONAL,NA,COMPLETED,NYU Langone Health,therapeutic,Interventional study
NCT05483257,Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,COMPLETED,BAIYONG SHEN,biomarker,Biomarker or molecular study
NCT05495685,iDentification and vAlidation Model of Liquid biopsY Based cfDNA Methylation and pRotEin biomArKers for Pancreatic Cancer (DAYBREAK Study),OBSERVATIONAL,Unknown,UNKNOWN,Changhai Hospital,biomarker,Biomarker or molecular study
NCT05497531,Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers,INTERVENTIONAL,NA,RECRUITING,"University of California, Irvine",therapeutic,Interventional study
NCT05497778,A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.,INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT05514171,Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline,OBSERVATIONAL,Unknown,COMPLETED,Hospital del Mar,biomarker,Biomarker or molecular study
NCT05518110,PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Cancer Trials Ireland,therapeutic,Interventional study
NCT05518903,Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE2,RECRUITING,Mayo Clinic,therapeutic,Interventional study
NCT05519930,Pancreatic Cancer Early Detection Registry,OBSERVATIONAL,Unknown,COMPLETED,Hoag Memorial Hospital Presbyterian,biomarker,Biomarker or molecular study
NCT05524090,PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),other,Does not match therapeutic or biomarker criteria
NCT05535894,Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,West Virginia University,biomarker,Biomarker or molecular study
NCT05562297,"Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer",INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Shanghai Zhongshan Hospital,therapeutic,Interventional study
NCT05573776,A Pilot Study of the Effect of High Protein Supplement and Exercise Therapy on Preservation of Skeletal Muscle Mass and Quality of Life in Patients With Gastric Cancer and Pancreatic Cancer Treated With Chemotherapy,INTERVENTIONAL,NA,COMPLETED,Yonsei University,therapeutic,Interventional study
NCT05580445,"Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE1,UNKNOWN,Shouyao Holdings (Beijing) Co. LTD,therapeutic,Interventional study
NCT05585554,Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy,INTERVENTIONAL,NA,NOT_YET_RECRUITING,Viewray Inc.,therapeutic,Interventional study
NCT05586516,A Study to Assess an ATX Inhibitor (IOA-289) in Patients with Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,iOnctura,therapeutic,Interventional study
NCT05589480,Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection,OBSERVATIONAL,Unknown,COMPLETED,Luo Cong,biomarker,Biomarker or molecular study
NCT05591287,"Contrast Enhanced Harmonic Endoscopic Ultrasound (CH-EUS), Elastography, and Fractal Analysis in Predicting Pancreatic Cancer Aggressiveness and Response to Therapy.",OBSERVATIONAL,Unknown,UNKNOWN,Istituto Clinico Humanitas,biomarker,Biomarker or molecular study
NCT05596435,Early Detection of Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Tianjin Medical University Cancer Institute and Hospital,biomarker,Biomarker or molecular study
NCT05601323,A Study of Suizenji in Patients With Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,SONIRE Therapeutics Inc.,therapeutic,Interventional study
NCT05604573,DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer,OBSERVATIONAL,Unknown,UNKNOWN,Seoul National University Hospital,biomarker,Biomarker or molecular study
NCT05621824,A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS,OBSERVATIONAL,Unknown,NOT_YET_RECRUITING,Peking Union Medical College Hospital,other,Early detection / screening study
NCT05624918,A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,RECRUITING,Ashish Manne,therapeutic,Interventional study
NCT05630989,A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy,OBSERVATIONAL,Unknown,RECRUITING,"Mandana Kamgar, MD",biomarker,Biomarker or molecular study
NCT05632328,AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Bruno Bockorny,therapeutic,Interventional study
NCT05634525,Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients,INTERVENTIONAL,PHASE1,WITHDRAWN,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT05638698,Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,University of Kansas Medical Center,therapeutic,Interventional study
NCT05642962,Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC),INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT05653453,Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,RECRUITING,"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd",therapeutic,Interventional study
NCT05657743,A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,Alpha Tau Medical LTD.,therapeutic,Interventional study
NCT05659914,Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),therapeutic,Interventional study
NCT05669482,Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,"Verastem, Inc.",therapeutic,Interventional study
NCT05673811,Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Theriva Biologics SL,therapeutic,Interventional study
NCT05681390,Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,First Affiliated Hospital Xi'an Jiaotong University,therapeutic,Interventional study
NCT05721846,Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer,INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,"Inna Chen, MD",therapeutic,Interventional study
NCT05722223,Trimodal Prehabilitation in Pancreatic Cancer Patients Urdergoing Neoadjuvant Treatment,INTERVENTIONAL,NA,COMPLETED,Puerta de Hierro University Hospital,therapeutic,Interventional study
NCT05727319,Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC),OBSERVATIONAL,Unknown,COMPLETED,NHS Greater Glasgow and Clyde,other,Does not match therapeutic or biomarker criteria
NCT05729737,Radiographic Response to Chemotherapy in Unresected Localized Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,Peking Union Medical College Hospital,biomarker,Biomarker or molecular study
NCT05751850,"HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE3,RECRUITING,"Jiangsu HengRui Medicine Co., Ltd.",therapeutic,Interventional study
NCT05776524,Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,THERABIONIC INC.,therapeutic,Interventional study
NCT05783076,SBRT Plus vNKT for Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Changhai Hospital,therapeutic,Interventional study
NCT05788744,Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,Copenhagen University Hospital at Herlev,therapeutic,Interventional study
NCT05795920,Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",therapeutic,Interventional study
NCT05802407,The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,Peking Union Medical College Hospital,therapeutic,Interventional study
NCT05802420,The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,NA,UNKNOWN,Peking Union Medical College Hospital,therapeutic,Interventional study
NCT05810792,Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Sahlgrenska University Hospital,therapeutic,Interventional study
NCT05827055,Proglumide and Chemotherapy for Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Georgetown University,therapeutic,Interventional study
NCT05827796,IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,RECRUITING,"InxMed (Shanghai) Co., Ltd.",therapeutic,Interventional study
NCT05830019,Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery,INTERVENTIONAL,NA,UNKNOWN,Shanghai Proton and Heavy Ion Center,therapeutic,Interventional study
NCT05836870,Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE3,RECRUITING,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT05841706,Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,TERMINATED,Jonsson Comprehensive Cancer Center,therapeutic,Interventional study
NCT05851924,A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC),INTERVENTIONAL,PHASE2,RECRUITING,Memorial Sloan Kettering Cancer Center,therapeutic,Interventional study
NCT05859750,A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Akeso,therapeutic,Interventional study
NCT05861336,GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,WITHDRAWN,Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS,therapeutic,Interventional study
NCT05875753,68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,UNKNOWN,Peking Union Medical College Hospital,therapeutic,Interventional study
NCT05884463,18F-FAPI PET Imaging in Pancreatic Adenocarcinoma,INTERVENTIONAL,NA,COMPLETED,Zhejiang University,therapeutic,Interventional study
NCT05906615,Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis,INTERVENTIONAL,PHASE2,COMPLETED,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),therapeutic,Interventional study
NCT05911243,"Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer",INTERVENTIONAL,NA,RECRUITING,University of Washington,therapeutic,Interventional study
NCT05919238,Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE1,RECRUITING,Impact Biotech Ltd,therapeutic,Interventional study
NCT05923567,New Predictive Marker for Pancreatic Cancer Using CA19-9 and Fecal Elastase,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Gangnam Severance Hospital,biomarker,Biomarker or molecular study
NCT05927142,Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy,INTERVENTIONAL,PHASE1,RECRUITING,"Joachim Aerts, MD PhD",therapeutic,Interventional study
NCT05955092,Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma,OBSERVATIONAL,Unknown,UNKNOWN,Peking Union Medical College Hospital,biomarker,Biomarker or molecular study
NCT05958849,Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,Zhejiang Cancer Hospital,therapeutic,Interventional study
NCT05973331,Prospective Validation of an EHR-based Pancreatic Cancer Risk Model,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Beth Israel Deaconess Medical Center,biomarker,Biomarker or molecular study
NCT05988814,Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy,INTERVENTIONAL,PHASE2,RECRUITING,Centre Georges Francois Leclerc,therapeutic,Interventional study
NCT05997147,A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma,OBSERVATIONAL,Unknown,UNKNOWN,Tianjin Medical University Cancer Institute and Hospital,biomarker,Biomarker or molecular study
NCT06006728,"Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy",OBSERVATIONAL,Unknown,COMPLETED,"University Hospital, Bordeaux",other,Does not match therapeutic or biomarker criteria
NCT06009029,SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study),INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Peking University Third Hospital,therapeutic,Interventional study
NCT06015659,ZN-c3 + Gemcitabine in Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,"Brandon Huffman, MD",therapeutic,Interventional study
NCT06015724,Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Georgetown University,therapeutic,Interventional study
NCT06018896,Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Fudan University,therapeutic,Interventional study
NCT06040801,"Effect of Geriatric Intervention in Frail Patients with Gastric, Biliary, and Pancreatic Cancer Receiving Palliative Chemotherapy",INTERVENTIONAL,NA,RECRUITING,Chang Gung Memorial Hospital,therapeutic,Interventional study
NCT06041009,Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations,OBSERVATIONAL,Unknown,RECRUITING,Qilu Hospital of Shandong University,biomarker,Biomarker or molecular study
NCT06044064,"""Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)"" - A Prospective Pilot Observational Study",OBSERVATIONAL,Unknown,NOT_YET_RECRUITING,"Asian Institute of Gastroenterology, India",biomarker,Biomarker or molecular study
NCT06048484,Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE2,RECRUITING,Gulam Manji,therapeutic,Interventional study
NCT06050317,Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Shandong Cancer Hospital and Institute,therapeutic,Interventional study
NCT06051851,Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,therapeutic,Interventional study
NCT06060405,Durvalumab and Oleclumab in Resectable PDAC,INTERVENTIONAL,PHASE2,RECRUITING,"University Health Network, Toronto",therapeutic,Interventional study
NCT06069778,"Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma",INTERVENTIONAL,PHASE1,TERMINATED,BioNTech SE,therapeutic,Interventional study
NCT06078787,Olaparib in PALB2 Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Azienda Ospedaliero-Universitaria di Modena,therapeutic,Interventional study
NCT06079346,A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Oncotelic Inc.,therapeutic,Interventional study
NCT06080854,AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,therapeutic,Interventional study
NCT06090825,Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient,OBSERVATIONAL,Unknown,UNKNOWN,Peking Union Medical College Hospital,biomarker,Biomarker or molecular study
NCT06090916,Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,Jonsson Comprehensive Cancer Center,therapeutic,Interventional study
NCT06094140,NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer,INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,Australasian Gastro-Intestinal Trials Group,therapeutic,Interventional study
NCT06110598,CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X),INTERVENTIONAL,PHASE2,WITHDRAWN,Case Comprehensive Cancer Center,therapeutic,Interventional study
NCT06122480,Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,NA,RECRUITING,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,therapeutic,Interventional study
NCT06129422,"Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,"Nihon Medi-Physics Co., Ltd.",therapeutic,Interventional study
NCT06129812,An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Seoul National University Hospital,biomarker,Biomarker or molecular study
NCT06132087,PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy,INTERVENTIONAL,NA,ACTIVE_NOT_RECRUITING,University of Southern California,therapeutic,Interventional study
NCT06134765,Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer,INTERVENTIONAL,PHASE2,UNKNOWN,"Second Affiliated Hospital, School of Medicine, Zhejiang University",therapeutic,Interventional study
NCT06139042,"Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers",OBSERVATIONAL,Unknown,RECRUITING,"Second Affiliated Hospital, School of Medicine, Zhejiang University",biomarker,Biomarker or molecular study
NCT06144762,Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,Institut du Cancer de Montpellier - Val d'Aurelle,therapeutic,Interventional study
NCT06149546,Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial),INTERVENTIONAL,NA,RECRUITING,Cancer Trials Ireland,therapeutic,Interventional study
NCT06149689,mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Fudan University,therapeutic,Interventional study
NCT06151223,A Prospective Registry for Patients at High-Risk for Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,Mayo Clinic,biomarker,Biomarker or molecular study
NCT06151262,A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,therapeutic,Interventional study
NCT06151691,Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach,OBSERVATIONAL,Unknown,UNKNOWN,Fudan University,other,Does not match therapeutic or biomarker criteria
NCT06158139,Autologous CAR-T Cells Targeting B7-H3 in PDAC,INTERVENTIONAL,PHASE1,RECRUITING,UNC Lineberger Comprehensive Cancer Center,therapeutic,Interventional study
NCT06159478,Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume),INTERVENTIONAL,PHASE2,RECRUITING,"National Cancer Center, Japan",therapeutic,Interventional study
NCT06160323,Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,Chinese University of Hong Kong,therapeutic,Interventional study
NCT06164691,Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer,INTERVENTIONAL,NA,TERMINATED,Matthew Neal MD,therapeutic,Interventional study
NCT06166147,A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection,OBSERVATIONAL,Unknown,RECRUITING,Fudan University,biomarker,Biomarker or molecular study
NCT06172036,Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Zhejiang University,therapeutic,Interventional study
NCT06172634,A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy,INTERVENTIONAL,PHASE1,UNKNOWN,Soonchunhyang University Hospital,therapeutic,Interventional study
NCT06173310,DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,University of Alabama at Birmingham,therapeutic,Interventional study
NCT06199466,A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,TERMINATED,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT06199895,"Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer",INTERVENTIONAL,PHASE2,RECRUITING,Liu Huang,therapeutic,Interventional study
NCT06203613,Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,YiHui Guan,therapeutic,Interventional study
NCT06203821,Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Aram Hezel,therapeutic,Interventional study
NCT06206876,FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE1,WITHDRAWN,Roswell Park Cancer Institute,therapeutic,Interventional study
NCT06208436,The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,Tianjin Medical University Cancer Institute and Hospital,other,Does not match therapeutic or biomarker criteria
NCT06217042,"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer",INTERVENTIONAL,PHASE3,NOT_YET_RECRUITING,Fudan University,therapeutic,Interventional study
NCT06233877,Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Hirschfeld Oncology,therapeutic,Interventional study
NCT06241352,Statin Addition to Chemotherapy for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,COMPLETED,Changhai Hospital,therapeutic,Interventional study
NCT06250972,Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,RECRUITING,Fudan University,therapeutic,Interventional study
NCT06255912,Clinical Trial for Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",therapeutic,Interventional study
NCT06259058,Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Tianjin Medical University Cancer Institute and Hospital,therapeutic,Interventional study
NCT06261359,A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE2,RECRUITING,"Qilu Pharmaceutical Co., Ltd.",therapeutic,Interventional study
NCT06267690,A CT-based Radiomics Model to Predict Survival-graded Fibrosis in PDAC,OBSERVATIONAL,Unknown,COMPLETED,"First Affiliated Hospital, Sun Yat-Sen University",biomarker,Biomarker or molecular study
NCT06272162,Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy,INTERVENTIONAL,NA,NOT_YET_RECRUITING,UMC Utrecht,therapeutic,Interventional study
NCT06275737,"POP-UP: a Single-arm, Two-cohort Study: Trimodal Prehab for Upper GI and Pancreatic Cancer",INTERVENTIONAL,NA,RECRUITING,GERCOR - Multidisciplinary Oncology Cooperative Group,therapeutic,Interventional study
NCT06278454,Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC),INTERVENTIONAL,PHASE1,RECRUITING,Chengdu New Radiomedicine Technology Co. LTD.,therapeutic,Interventional study
NCT06278493,A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",therapeutic,Interventional study
NCT06282809,The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy,INTERVENTIONAL,NA,RECRUITING,"HistoSonics, Inc.",therapeutic,Interventional study
NCT06305728,"Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms",OBSERVATIONAL,Unknown,RECRUITING,Memorial Sloan Kettering Cancer Center,biomarker,Biomarker or molecular study
NCT06307080,Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis,INTERVENTIONAL,NA,RECRUITING,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",therapeutic,Interventional study
NCT06320717,AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma,OBSERVATIONAL,Unknown,RECRUITING,Roswell Park Cancer Institute,biomarker,Biomarker or molecular study
NCT06344299,Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma,OBSERVATIONAL,Unknown,COMPLETED,Fudan University,biomarker,Biomarker or molecular study
NCT06345599,PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study),INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Second Affiliated Hospital of Soochow University,therapeutic,Interventional study
NCT06361030,Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",therapeutic,Interventional study
NCT06361316,Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,Kuirong Jiang,therapeutic,Interventional study
NCT06361888,"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE2,RECRUITING,Hutchmed,therapeutic,Interventional study
NCT06370754,Newly Emerging Immunotherapy for Pancreatic Cancer Treatment,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Fudan University,therapeutic,Interventional study
NCT06375473,Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients,OBSERVATIONAL,Unknown,RECRUITING,Peking Union Medical College Hospital,biomarker,Biomarker or molecular study
NCT06378853,Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma Patients,OBSERVATIONAL,Unknown,COMPLETED,"Jinling Hospital, China",biomarker,Biomarker or molecular study
NCT06387368,Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer,INTERVENTIONAL,PHASE4,NOT_YET_RECRUITING,Xi'an Jiaotong University,therapeutic,Interventional study
NCT06389760,Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,therapeutic,Interventional study
NCT06391892,Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery,INTERVENTIONAL,PHASE3,RECRUITING,Elisabethinen Hospital,therapeutic,Interventional study
NCT06393166,Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Zhejiang Cancer Hospital,therapeutic,Interventional study
NCT06395337,Multimodal Imaging in Rectal Cancer & Pancreatic Cancer,INTERVENTIONAL,PHASE1,UNKNOWN,Radboud University Medical Center,therapeutic,Interventional study
NCT06396637,PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC,INTERVENTIONAL,PHASE2,RECRUITING,Sun Yat-sen University,therapeutic,Interventional study
NCT06398587,"Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma",INTERVENTIONAL,PHASE2,WITHDRAWN,OHSU Knight Cancer Institute,therapeutic,Interventional study
NCT06399172,OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy,OBSERVATIONAL,Unknown,NOT_YET_RECRUITING,OncoSil Medical Limited,other,Does not match therapeutic or biomarker criteria
NCT06404840,"Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study",INTERVENTIONAL,PHASE2,RECRUITING,Tianjin Medical University Cancer Institute and Hospital,therapeutic,Interventional study
NCT06405490,NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC,INTERVENTIONAL,PHASE2,RECRUITING,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",therapeutic,Interventional study
NCT06405685,Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis,INTERVENTIONAL,PHASE2,UNKNOWN,Tianjin Medical University Cancer Institute and Hospital,therapeutic,Interventional study
NCT06411470,Gastrointestinal Microflora and Serum Metabolomics in Patients With Pancreatic Cancer and Chronic Pancreatitis,OBSERVATIONAL,Unknown,RECRUITING,Changhai Hospital,biomarker,Biomarker or molecular study
NCT06412510,"Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT",INTERVENTIONAL,PHASE1,RECRUITING,Case Comprehensive Cancer Center,therapeutic,Interventional study
NCT06423963,Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,H. Lee Moffitt Cancer Center and Research Institute,therapeutic,Interventional study
NCT06427239,Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,RECRUITING,Fudan University,therapeutic,Interventional study
NCT06427447,Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC),INTERVENTIONAL,PHASE3,RECRUITING,Changhai Hospital,therapeutic,Interventional study
NCT06435260,Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Hebei Medical University Fourth Hospital,therapeutic,Interventional study
NCT06464965,Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer,INTERVENTIONAL,PHASE1,COMPLETED,Zhejiang Provincial People's Hospital,therapeutic,Interventional study
NCT06478459,Endoscopic Ultrasound (EUS) Intratumoral Injection of CAR-NK Cells in the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,RECRUITING,Zhejiang University,therapeutic,Interventional study
NCT06491472,Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",therapeutic,Interventional study
NCT06492941,A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,NOT_YET_RECRUITING,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",therapeutic,Interventional study
NCT06496373,Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,RECRUITING,Ruijin Hospital,therapeutic,Interventional study
NCT06497777,The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,National Taiwan University Hospital,biomarker,Biomarker or molecular study
NCT06498518,"A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE2,WITHDRAWN,Karen Carty,therapeutic,Interventional study
NCT06513455,Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Harbin Medical University,therapeutic,Interventional study
NCT06515587,Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",therapeutic,Interventional study
NCT06518538,Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,WITHDRAWN,Cornerstone Pharmaceuticals,therapeutic,Interventional study
NCT06528093,A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy,INTERVENTIONAL,PHASE1,TERMINATED,Boehringer Ingelheim,therapeutic,Interventional study
NCT06532344,"An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE1,ACTIVE_NOT_RECRUITING,Ono Pharmaceutical Co. Ltd,therapeutic,Interventional study
NCT06538207,"An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE1,COMPLETED,Ono Pharmaceutical Co. Ltd,therapeutic,Interventional study
NCT06547736,Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Fudan University,therapeutic,Interventional study
NCT06571461,Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer,INTERVENTIONAL,PHASE3,NOT_YET_RECRUITING,"CSPC Ouyi Pharmaceutical Co., Ltd.",therapeutic,Interventional study
NCT06576115,"Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE2,RECRUITING,Barbara Ann Karmanos Cancer Institute,therapeutic,Interventional study
NCT06585072,Pancreatic Cancer and Diabetes Mellitus,OBSERVATIONAL,Unknown,RECRUITING,Shanghai Changzheng Hospital,other,Does not match therapeutic or biomarker criteria
NCT06598033,Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Fudan University,therapeutic,Interventional study
NCT06600906,Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,"University of California, San Francisco",biomarker,Biomarker or molecular study
NCT06601283,Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Fudan University,therapeutic,Interventional study
NCT06602037,ImmunoPET Imaging of Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,RenJi Hospital,therapeutic,Interventional study
NCT06616688,Innovative Therapeutic Treatments to Inhibit Perineural Invasion in Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,NOT_YET_RECRUITING,IRCCS San Raffaele,other,Does not match therapeutic or biomarker criteria
NCT06621095,Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001),INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,RenJi Hospital,therapeutic,Interventional study
NCT06630325,"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer",INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,OHSU Knight Cancer Institute,therapeutic,Interventional study
NCT06639724,Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer,INTERVENTIONAL,PHASE1,RECRUITING,"University of California, San Diego",therapeutic,Interventional study
NCT06651580,"Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study",OBSERVATIONAL,Unknown,RECRUITING,M.D. Anderson Cancer Center,biomarker,Biomarker or molecular study
NCT06659705,Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI),INTERVENTIONAL,PHASE2,RECRUITING,Institut Curie,therapeutic,Interventional study
NCT06662669,YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Shanghai YingLi Pharmaceutical Co. Ltd.,therapeutic,Interventional study
NCT06669078,NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,therapeutic,Interventional study
NCT06700603,Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,"Rui-hua Xu, MD, PhD",therapeutic,Interventional study
NCT06705335,Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,NOT_YET_RECRUITING,Institut Bergonié,other,Does not match therapeutic or biomarker criteria
NCT06736678,Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients,INTERVENTIONAL,NA,RECRUITING,Sun Yat-sen University,therapeutic,Interventional study
NCT06736717,Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE1,RECRUITING,University of Kansas Medical Center,therapeutic,Interventional study
NCT06743386,Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP ),INTERVENTIONAL,NA,NOT_YET_RECRUITING,French Society of Digestive Endoscopy,therapeutic,Interventional study
NCT06755359,Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer,INTERVENTIONAL,NA,NOT_YET_RECRUITING,Alpha Tau Medical LTD.,therapeutic,Interventional study
NCT06757244,"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer",INTERVENTIONAL,PHASE2,RECRUITING,Hopital Foch,therapeutic,Interventional study
NCT06758544,"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer",INTERVENTIONAL,PHASE1,RECRUITING,Guangdong Provincial People's Hospital,therapeutic,Interventional study
NCT06759090,Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Zhejiang University,therapeutic,Interventional study
NCT06760234,Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis,OBSERVATIONAL,Unknown,COMPLETED,"Second Affiliated Hospital, School of Medicine, Zhejiang University",biomarker,Biomarker or molecular study
NCT06766019,"Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer",INTERVENTIONAL,PHASE2,ACTIVE_NOT_RECRUITING,The First Affiliated Hospital with Nanjing Medical University,therapeutic,Interventional study
NCT06770452,HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients,INTERVENTIONAL,PHASE2,RECRUITING,Zhejiang University,therapeutic,Interventional study
NCT06773130,HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE1,RECRUITING,West China Hospital,therapeutic,Interventional study
NCT06777030,Role of Exosomes in Pancreatic Cancer Progression,OBSERVATIONAL,Unknown,RECRUITING,IRCCS Azienda Ospedaliero-Universitaria di Bologna,other,Does not match therapeutic or biomarker criteria
NCT06779318,Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis,INTERVENTIONAL,PHASE4,NOT_YET_RECRUITING,The First Affiliated Hospital with Nanjing Medical University,therapeutic,Interventional study
NCT06790602,Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,RECRUITING,"University of California, San Diego",therapeutic,Interventional study
NCT06809374,Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer,OBSERVATIONAL,Unknown,COMPLETED,Kochi University,biomarker,Biomarker or molecular study
NCT06833658,Effects of Aromatherapy with Essential Oils on Anxiety and Depression in Perioperative Patients with Pancreatic Cancer,INTERVENTIONAL,NA,NOT_YET_RECRUITING,Peking University First Hospital,therapeutic,Interventional study
NCT06840067,Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.,INTERVENTIONAL,NA,RECRUITING,Gansu Wuwei Tumor Hospital,therapeutic,Interventional study
NCT06844422,Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND),INTERVENTIONAL,PHASE1,RECRUITING,Shandong Cancer Hospital and Institute,therapeutic,Interventional study
NCT06849063,Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE,OBSERVATIONAL,Unknown,RECRUITING,Yu Shi,other,Does not match therapeutic or biomarker criteria
NCT06861088,The Effect of Kinisoquin on Thromboembolic Events in Patients With Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE3,RECRUITING,Quercis Pharma AG,therapeutic,Interventional study
NCT06861543,"The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)",INTERVENTIONAL,PHASE1,RECRUITING,Peking Union Medical College Hospital,therapeutic,Interventional study
NCT06867172,Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,RECRUITING,Carol Davila University of Medicine and Pharmacy,other,Does not match therapeutic or biomarker criteria
NCT06873178,The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,China-Japan Friendship Hospital,other,Does not match therapeutic or biomarker criteria
NCT06888648,Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Zhejiang University,therapeutic,Interventional study
NCT06888674,Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Zhejiang University,therapeutic,Interventional study
NCT06892054,Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),therapeutic,Interventional study
NCT06893536,Impact of Perioperative Nutritional Status and Management in the Context of Resectable Pancreatic Adenocarcinoma,OBSERVATIONAL,Unknown,RECRUITING,"University Hospital, Strasbourg, France",biomarker,Biomarker or molecular study
NCT06896188,"9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)",INTERVENTIONAL,PHASE1,RECRUITING,Anwaar Saeed,therapeutic,Interventional study
NCT06898385,A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation,INTERVENTIONAL,PHASE1,RECRUITING,Sun Yat-sen University,therapeutic,Interventional study
NCT06904378,Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Washington University School of Medicine,therapeutic,Interventional study
NCT06906562,"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations",INTERVENTIONAL,PHASE2,RECRUITING,Sameek Roychowdhury,therapeutic,Interventional study
NCT06921252,Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?,OBSERVATIONAL,Unknown,COMPLETED,Kochi University,other,Does not match therapeutic or biomarker criteria
NCT06938906,Multimodal Therapy Impact on Pancreatic Cancer Survival,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,National Cheng Kung University,biomarker,Biomarker or molecular study
NCT06941987,Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer,OBSERVATIONAL,Unknown,NOT_YET_RECRUITING,Shanghai Zhongshan Hospital,biomarker,Biomarker or molecular study
NCT06944587,A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,Oslo University Hospital,biomarker,Biomarker or molecular study
NCT06946420,SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy,INTERVENTIONAL,PHASE3,ACTIVE_NOT_RECRUITING,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,therapeutic,Interventional study
NCT06946901,"The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial",INTERVENTIONAL,PHASE2,RECRUITING,Shanghai Zhongshan Hospital,therapeutic,Interventional study
NCT06947395,Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI),OBSERVATIONAL,Unknown,COMPLETED,"Immunovia, Inc.",biomarker,Biomarker or molecular study
NCT06958328,Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,RECRUITING,NRG Oncology,therapeutic,Interventional study
NCT06978322,Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,Minia University,biomarker,Biomarker or molecular study
NCT06984562,Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer,INTERVENTIONAL,NA,RECRUITING,Fox Chase Cancer Center,therapeutic,Interventional study
NCT06991491,Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004),INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,West China Hospital,therapeutic,Interventional study
NCT07034339,Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution,OBSERVATIONAL,Unknown,RECRUITING,First Affiliated Hospital of Zhejiang University,biomarker,Biomarker or molecular study
NCT07036978,Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer,OBSERVATIONAL,Unknown,NOT_YET_RECRUITING,Chang Gung Memorial Hospital,biomarker,Biomarker or molecular study
NCT07044453,Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,"University Hospital, Rouen",therapeutic,Interventional study
NCT07054879,CtDNA-guided Maintenance Therapy in Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,biomarker,Biomarker or molecular study
NCT07055568,"A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic Cancer",INTERVENTIONAL,NA,NOT_YET_RECRUITING,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",therapeutic,Interventional study
NCT07066098,"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)",INTERVENTIONAL,PHASE3,RECRUITING,Innovent Biologics (Suzhou) Co. Ltd.,therapeutic,Interventional study
NCT07076121,A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30),INTERVENTIONAL,PHASE2,RECRUITING,Bristol-Myers Squibb,therapeutic,Interventional study
NCT07089940,OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,EARLY_PHASE1,NOT_YET_RECRUITING,OHSU Knight Cancer Institute,therapeutic,Interventional study
NCT07097064,Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Institut du Cancer de Montpellier - Val d'Aurelle,therapeutic,Interventional study
NCT07104864,Early Detection of PDAC in Patients With Chronic Pancreatitis,OBSERVATIONAL,Unknown,COMPLETED,First Affiliated Hospital Xi'an Jiaotong University,biomarker,Biomarker or molecular study
NCT07108504,Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Shanghai Zhongshan Hospital,therapeutic,Interventional study
NCT07114315,A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Akeso,therapeutic,Interventional study
NCT07114666,XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer,INTERVENTIONAL,NA,NOT_YET_RECRUITING,Peking Union Medical College Hospital,therapeutic,Interventional study
NCT07117045,Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer,OBSERVATIONAL,Unknown,RECRUITING,Changhai Hospital,other,Early detection / screening study
NCT07124611,A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer,INTERVENTIONAL,NA,NOT_YET_RECRUITING,Ohio State University Comprehensive Cancer Center,therapeutic,Interventional study
NCT07132060,MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer,INTERVENTIONAL,NA,NOT_YET_RECRUITING,"Clinica Universidad de Navarra, Universidad de Navarra",therapeutic,Interventional study
NCT07138846,A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE3,NOT_YET_RECRUITING,Shanghai Miracogen Inc.,therapeutic,Interventional study
NCT07155629,Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer,INTERVENTIONAL,PHASE3,NOT_YET_RECRUITING,Helsinki University Central Hospital,therapeutic,Interventional study
NCT07155850,Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC,INTERVENTIONAL,NA,NOT_YET_RECRUITING,BetaGlue Therapeutics SpA,therapeutic,Interventional study
NCT07157605,Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID),OBSERVATIONAL,Unknown,RECRUITING,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),biomarker,Biomarker or molecular study
NCT07173374,Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Shandong Cancer Hospital and Institute,therapeutic,Interventional study
NCT07173387,Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Shandong Cancer Hospital and Institute,therapeutic,Interventional study
NCT07198659,A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,RECRUITING,The First Affiliated Hospital of Air Force Medicial University,therapeutic,Interventional study
NCT07208539,AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Shanghai Zhongshan Hospital,therapeutic,Interventional study
NCT07214298,Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Roswell Park Cancer Institute,therapeutic,Interventional study
NCT07217717,Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC),INTERVENTIONAL,PHASE3,RECRUITING,SOFIE,therapeutic,Interventional study
NCT07219238,"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)",INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,GE Healthcare,therapeutic,Interventional study
NCT07226856,"BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma",INTERVENTIONAL,PHASE2,RECRUITING,Mayo Clinic,therapeutic,Interventional study
NCT07230301,Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,Sizhen Wang,therapeutic,Interventional study
NCT07231094,"A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer",INTERVENTIONAL,EARLY_PHASE1,NOT_YET_RECRUITING,The Third Xiangya Hospital of Central South University,therapeutic,Interventional study
NCT07232875,HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE3,NOT_YET_RECRUITING,"Jiangsu HengRui Medicine Co., Ltd.",therapeutic,Interventional study
NCT07238283,"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer",INTERVENTIONAL,PHASE3,RECRUITING,"Jiangsu HengRui Medicine Co., Ltd.",therapeutic,Interventional study
NCT07241676,Early Recurrence After Surgery for Pancreatic Cancer,OBSERVATIONAL,Unknown,ENROLLING_BY_INVITATION,Azienda Ospedaliera di Padova,other,Does not match therapeutic or biomarker criteria
NCT07243288,Evaluation of an Early Radiomic Signature in Patients With Metastatic Pancreatic Adenocarcinoma Treated With First-line Chemotherapy,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Assistance Publique - Hôpitaux de Paris,biomarker,Biomarker or molecular study
NCT07252076,PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa,OBSERVATIONAL,Unknown,RECRUITING,Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria,biomarker,Biomarker or molecular study
NCT07252232,Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC),INTERVENTIONAL,PHASE3,RECRUITING,"Revolution Medicines, Inc.",therapeutic,Interventional study
NCT07254091,Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer,INTERVENTIONAL,EARLY_PHASE1,NOT_YET_RECRUITING,Northwell Health,therapeutic,Interventional study
NCT07255001,Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life,INTERVENTIONAL,NA,NOT_YET_RECRUITING,British Columbia Cancer Agency,therapeutic,Interventional study
NCT07255404,A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,BioNTech SE,therapeutic,Interventional study
NCT07259317,Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma,INTERVENTIONAL,PHASE2,RECRUITING,Corcept Therapeutics,therapeutic,Interventional study
NCT07269626,PULSAR in Systemic Therapy for Pancreatic Cancer,INTERVENTIONAL,PHASE2,RECRUITING,Samsung Medical Center,therapeutic,Interventional study
NCT07283705,A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer,INTERVENTIONAL,PHASE2,NOT_YET_RECRUITING,M.D. Anderson Cancer Center,therapeutic,Interventional study
NCT07284277,TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC),INTERVENTIONAL,PHASE1,RECRUITING,"Clinica Universidad de Navarra, Universidad de Navarra",therapeutic,Interventional study
NCT07302841,Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer,INTERVENTIONAL,PHASE4,NOT_YET_RECRUITING,Tianjin Medical University Cancer Institute and Hospital,therapeutic,Interventional study
NCT07324096,A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer,INTERVENTIONAL,NA,NOT_YET_RECRUITING,Mayo Clinic,therapeutic,Interventional study
NCT07326150,Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer,OBSERVATIONAL,Unknown,ACTIVE_NOT_RECRUITING,Zhejiang Cancer Hospital,biomarker,Biomarker or molecular study
NCT07329920,Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy,OBSERVATIONAL,Unknown,COMPLETED,Guo ShiWei,biomarker,Biomarker or molecular study
NCT07336953,"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)",INTERVENTIONAL,PHASE3,NOT_YET_RECRUITING,West China Hospital,therapeutic,Interventional study
NCT07340151,Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma,INTERVENTIONAL,NA,NOT_YET_RECRUITING,The University of Texas Health Science Center at San Antonio,therapeutic,Interventional study
NCT07342231,FAPi PET in Pancreatic Ductal Adenocarcinoma,OBSERVATIONAL,Unknown,RECRUITING,Tata Memorial Hospital,biomarker,Biomarker or molecular study
NCT07342725,Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Ruijin Hospital,therapeutic,Interventional study
NCT07348107,ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.,INTERVENTIONAL,PHASE1,NOT_YET_RECRUITING,Daniel Breadner,therapeutic,Interventional study
NCT07353645,KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer,INTERVENTIONAL,PHASE1,RECRUITING,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,therapeutic,Interventional study
